Low-dose IL-2 reduces IL-21[+] T cells and induces a long-lived anti-inflammatory gene expression signature inversely modulated in COVID-19 patients

Jia-Yuan Zhang[1], Fiona Hamey[1], Dominik Trzupek[1], Marius Mickunas[2], Mercede Lee[1], Leila Godfrey[1], Jennie H.M. Yang[2], Marcin L Pekalski[1], Jane Kennet[3,4], Frank Waldron-Lynch[5], Mark L. Evans[3,4], Timothy I. M. Tree[2], Linda S. Wicker[1†], John A. Todd[1†] and Ricardo C. Ferreira[1†]

[1]JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.

[2]Department of Immunobiology, King's College London, School of Immunology and Microbial Sciences, London, United Kingdom.

[3]Wellcome-MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Cambridge, United Kingdom.

[4]National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Biomedical Campus, Cambridge, United Kingdom.

[5]Vertex Pharmaceuticals, Vertex Cell & Gene Therapies, Boston, Massachusetts, United States of America.

[†]Co-senior authors

Correspondence:

Prof. John A. Todd:

Email: john.todd@well.ox.ac.uk

Dr. Ricardo C. Ferreira:

Email: ricardo.ferreira@well.ox.ac.uk

Abstract

Despite early clinical successes, the mechanisms of action of low-dose interleukin-2 (LD-IL-2) immunotherapy remain only partly understood. Here, we examined the effects of interval administration of low-dose recombinant IL-2 (iLD-IL-2) using high-resolution, single-cell multiomics and flow cytometry. We confirmed that iLD-IL-2 selectively expands thymic-derived FOXP3$^+$HELIOS$^+$ Tregs and CD56^{br} NK cells, and showed that treatment reduced the frequency of IL-21-producing CD4$^+$ T cells and of two subsets of innate-like CD8$^+$ T cells, mucosal-associated invariant T cells and V$_{\gamma9}$V$_{\delta2}$ T cells. The cellular changes induced by LD-IL-2 were associated with an anti-inflammatory gene expression signature, which remains detectable in all T and NK cell subsets analysed one month after treatment. The anti-inflammatory nature of this gene expression signature was supported by the observation that the same genes were also modulated in COVID-19 patients, but in the opposite direction. These findings warrant continued investigations of the potential clinical benefits of iLD-IL-2 in immunotherapy and further understanding of the development of long-term sequelae in convalescent COVID-19 patients.

Introduction

The use of much lower doses of interleukin-2 (IL-2) than employed in cancer therapy has shown clinical efficacy in a number of inflammatory and autoimmune conditions, by stimulating a subset of CD4[+] T cells expressing high levels of the high-affinity trimeric IL-2 receptor, designated as regulatory T cells (Tregs)[1–9]. In the autoimmune disease type 1 diabetes (T1D), the genetic association with the IL-2 pathway in mice[10] and in humans[11,12], combined with preclinical studies[13,14], have provided a strong rationale for the development of low-dose (LD)-IL-2 immunotherapy. Safety and dose determination studies in T1D have been informative and underpin future clinical trials in T1D[15–18]. We have previously conducted an adaptive single-dose observational study (DILT1D), which demonstrated the sensitivity and specificity of IL-2 signalling *in vivo* and determined a dosing range of $0.2\text{-}0.47\times10^6$ IU/m^2 of recombinant IL-2 (aldesleukin/proleukin) to achieve Treg increases in blood in the order of 20-50% from baseline[18]. We then performed a second study (DILfrequency)[19] to determine how often to give low-dose aldesleukin to reliably induce a steady-state Treg induction whilst maintaining the selective expansion of Tregs and not effector T cells.

Here, we explored in depth the effects and pharmacodynamics of interval LD-IL-2 dosing (iLD-IL-2) in DILfrequency peripheral blood mononuclear cell (PBMC) samples. We employed a recently developed targeted multiomics approach, which allowed us to simultaneously quantify 565 mRNA transcripts and 65 surface protein targets at the single-cell level[20]. We performed a detailed immunophenotypic characterization of both T and NK cell compartments, with a particular emphasis on the CD4[+] CD127[low]CD25[hi] T cell and CD56[br] NK cell subsets, which have been previously shown to be highly sensitive to iLD-IL-2 treatment[18,19]. Aside from the expected expansions of thymic-derived FOXP3[+]HELIOS[+] Tregs and CD56[br] NK cells in T1D patients, we show that iLD-IL-2 reduces the frequency of IL-21-producing cells, a subset that has been previously implicated in the pathogenesis of T1D[21–23]. The reduction of IL-21-producing cells by iLD-IL-2 may provide therapeutic benefit in T1D since a recent clinical trial combining anti-IL-21 with liraglutide (to improve beta cell function) slowed the decline of C-peptide[24]. Unexpectedly, we discovered that iLD-IL-2 also induces an anti-inflammatory gene expression signature in both

T and NK cell subsets that continues to at least one month after cessation of treatment. Altered

expression of the same set of genes, but in the opposite direction, was found to be progressively

induced and sustained in COVID-19 patients, highlighting the anti-inflammatory nature of the

prolonged iLD-IL-2-induced gene changes. Taken together, our findings indicate that iLD-IL-2

can reduce IL-21 during treatment, and induce a suite of cellular alterations that promotes the

establishment of a long-lived anti-inflammatory environment.

Results

Interval administration of low-dose IL-2 (iLD-IL-2) induces and maintains increased frequencies of CD4$^+$ CD127^{low}CD25^{hi} T cells and CD56^{br} NK cells

The DILfrequency[19] study established an optimal three-day aldesleukin dosing interval, with doses ranging from 0.20-0.47 × 10^6 IU/m^2 (**Fig. 1a**). To gain further insight into the mechanism of action of iLD-IL-2, we selected 18 DILfrequency participants (adults with long-standing T1D) treated with this dosing regimen (**Supplementary Table 1**) and characterised the cellular alterations in blood by polychromatic flow-cytometry (FACS). We observed a sustained increase in the frequency of CD4$^+$ CD127^{low}CD25^{hi} T cells (henceforth designated as the CD4$^+$ Treg gate) during the dosing phase, but no alterations in the frequency of the broader CD4$^+$ conventional T (Tconv) or CD8$^+$ T cell populations (**Fig. 1b,c**), including in a subset of CD45RA$^-$CD62L$^-$ effector memory CD4$^+$ T cells (T$_{EM}$), known to be enriched for recently activated effector T cells (**Supplementary Fig. 1a-c**).

Outside the T cell compartment, iLD-IL-2 also caused sustained increased frequencies of a subset of CD56^{br} NK cells (**Fig. 1c**). This effect was more pronounced than the increase in CD4$^+$ Tregs and is consistent with the relatively high affinity of the CD56^{br} NK subset for IL-2, especially when compared to the bulk NK population[25,26]. We observed no alteration in the frequency of the classical CD56^{dim} NK cells, which represent the majority of CD56$^+$ NK cells in circulation. The IL-2-induced increase in CD4$^+$ Tregs and CD56^{br} NK cells was recapitulated when assessing absolute numbers of cells in circulation, although their relative low abundance in blood resulted in no discernible alteration in the numbers of either CD4$^+$ and CD8$^+$ T cells or CD56$^+$ NK cells (**Fig. 1d,e**). An increase in both frequency and numbers of CD56^{br} (but not CD56^{dim}) NK cells in blood was observed in all IL-2 dose groups (**Supplementary Fig. 1d-f**).

Investigating IL-2-induced cellular alterations in blood using single-cell multiomics

We next profiled PBMCs from 13 selected participants treated with the three-day interval dosing regimen (**Supplementary Table 1**) using a targeted single-cell multiomics approach, which

enables the parallel quantification of specific mRNA and cell-surface proteins (AbSeq) in each

cell[27]. To increase the power of this approach to identify small, yet potentially important, changes

elicited by iLD-IL-2, we have adopted a cell enrichment strategy to greatly increase the numbers

of CD4[+] Tregs and CD56[br] NK cells profiled in this study. In addition, we designed a custom

mRNA panel of 565 oligonucleotide probes, assessed in parallel with the expression of 65 cell-

surface protein targets (**Supplementary Table 2**)[20]. From each participant, we selected three

longitudinal blood samples on Day 0 (baseline), Day 27 (immediately before the last IL-2

injection) and Day 55 (four weeks after the last IL-2 dose), respectively. We then isolated five

immune populations from each sample following predefined proportions: 30% CD4[+] Tregs; 25%

CD4[+] Tconv and CD8[+] T cells 12% CD56[br] and 8% CD56[dim] NK cells, which were analysed with

or without *in vitro* stimulation (**Fig. 1f**). Unsupervised clustering of the 482,531 unstimulated cells

passing quality control (QC) revealed a clear delineation of the sorted T and NK cell populations,

identifying 15 distinct functional clusters (**Fig. 1g**). We observed good overlap among cells from

each participant, with similar representation in the five sorted immune populations

(**Supplementary Fig. 2a-c**). A similar result was observed for the clustering of the 323,839

stimulated cells passing QC (**Supplementary Fig. 2d-f**), indicating minimal batch effects that are

usually prevalent in scRNA-seq data.

In the unstimulated cells, we also identified two clusters characterised by the distinct co-expression

of a set of canonical cell cycle genes (see Methods), including *MKI67* (encoding for Ki-67), which

corresponded to cycling T and NK cells (**Supplementary Fig. 3a**). Overall, we found no evidence

that iLD-IL-2 was increasing the frequency of proliferating cells. Conversely, we found a reduction

in the frequency of proliferating CD56[br] NK cells and CD4[+] Tregs at Day 27 (**Supplementary**

Fig. 3b). Given the previously reported increased frequency of Ki-67[+] Tregs and CD56[br] NK cells

following LD-IL-2 treatment, we next investigated the frequency of proliferating cells by assessing

the intracellular expression of Ki-67 in patients treated with either single or multiple doses of LD-

IL2. In agreement with previous observations[4,28,29], we found a marked increased frequency of Ki-

67[+] cells in both CD4[+] Tregs and CD56[br] NK cells following the first dose of IL-2

(**Supplementary Fig. 3c,d**). In the multiple dosing cohort, we noted that this increased frequency

of Ki-67[+] cells persisted up to Day 27 only in CD56[br] NK, but not in the CD4[+] Treg cells

(**Supplementary Fig. 3d**). This discrepancy between the multiomics and FACS assessment of

proliferating CD56[br] NK cells may reflect a difference in the use of protein or mRNA markers to

assess cell cycle progression. Both *MKI67* (mRNA) and Ki-67 protein are synthesised and

accumulate during the S and G2/M phases of the cell cycle and show very good correlation in

synchronised cells[30]. However, in contrast to *MKI67*, Ki-67 protein is more long-lived, and can

still be detected in G1 after cell division[31]. The levels of Ki-67 protein in G1 depend on the rate of

protein accumulation during the S and G2/M phases, leading to the much higher rate of detection

of Ki-67[+] cells compared to the frequency of cells in the S-G/M phase (eg. 37% vs 1% in Fraction

II Tregs)[32]. Consistently, we found that 20% of total CD4[+] Tregs are Ki-67[+] at baseline, but only

~1% were identified as proliferating by multiomics analysis. These data indicate that in contrast

to Ki-67[+] protein levels, mRNA quantification allows a more specific identification of actively

dividing cells (in the S-G/M phases). Therefore, an explanation for the discrepancy between the

FACS and multiomics assessment of proliferating CD56[br] NK cells at Day 27, is that the increased

levels of Ki-67[+] cells reflect protein accumulation in recently divided G1 cells. In contrast, the

decrease in proliferating cells from the multiomics analysis reflects a reduction of actively dividing

cells in blood, possibly due to an increased likelihood for cells to enter the cell cycle in tissues as

IL-2 accumulates on the extracellular matrix during dosing[33–36].

Interval administration of low-dose IL-2 selectively expands FOXP3[+]HELIOS[+] Tregs

Next, we sought to investigate whether our iLD-IL-2 regimen altered the relative composition of

the cells sorted from the CD127[low]CD25[hi] Treg gate (**Supplementary Fig. 4**). Analysis of the

expression of the canonical Treg transcription factors *FOXP3* and *IKZF2* (encoding HELIOS)

allowed the stratification of CD127[low]CD25[hi] Treg clusters into three functional groups according

to their origin (**Supplementary Fig. 5** and **Methods**). Differential abundance analysis revealed an

enrichment in the frequency of naïve FOXP3[+]HELIOS[+] Tregs and a concomitant reduction of

CD25[+] FOXP3[−]HELIOS[−] Teffs on Day 27, after the conclusion of the four-week IL-2 dosing

phase, immediately before the last of the ten aldesleukin injections (**Fig. 2a,b**), which was

replicated in stimulated cells (**Fig. 2c,d**). Given the observed increase in CD127[low]CD25[hi] T cells

by FACS following LD-IL-2, we next investigated whether these changes were also reflected in

the absolute numbers in circulation, which were inferred from the relative frequencies identified

by single-cell analysis, scaled by the whole-blood CD127[low]CD25[hi] Treg counts. We found that

the IL-2 induced expansion on Day 27 was restricted to the thymic-derived FOXP3[+]HELIOS[+]

Treg subsets (**Fig. 2e**). We observed very good concordance between unstimulated and stimulated

conditions, with naïve Tregs showing >2-fold increase and memory FOXP3$^+$HELIOS$^+$ Tregs

displaying approximately a 70% increase in cell numbers compared to baseline pre-treatment

levels (**Fig. 2e**). In contrast, despite the expansion of CD127^{low}CD25^{hi} T cells, we obtained no

evidence of alterations in the number of activated CD25$^+$ FOXP3$^-$HELIOS$^-$ Teffs contained in this

population, even though they express the high affinity trimeric IL-2 receptor (**Fig. 2e**).

Furthermore, we observed no changes in the *in vitro* suppressive capacity of CD4$^+$

CD127^{low}CD25^{hi} T cells after IL-2 treatment on a per cell basis compared to the pre-treatment cells

(**Fig. 2f**). The alterations in the relative composition of CD127^{low}CD25^{hi} T cells were found to be

transient and reverted to baseline one month after the last dose of IL-2 (Day 55; **Supplementary**

Fig. 6a-d). In contrast, we observed no notable changes in the relative abundance of CD4$^+$CD25$^-$

$^{/low}$ Tconv subsets during or after IL-2 treatment (**Supplementary Fig. 7**).

Using pseudo-time analysis, we identified a single trajectory of FOXP3$^+$ Treg differentiation

among CD4$^+$ T cells, stemming from the conventional naïve Tregs towards the classical HLA-II$^+$

effector Treg subset (**Supplementary Fig. 8a-c**). In agreement with our compositional analysis,

we found a significantly increased ratio of naïve to HLA-II$^+$ Tregs at Day 27 (**Supplementary**

Fig. 8d). Notably, there was no alteration in the differentiation status of Tregs in response to iLD-

IL-2, as illustrated by the overlapping pseudo-time distribution within the Treg differentiation

trajectory between Days 0, 27 and 55 (**Supplementary Fig. 8d**). These data indicate that iLD-IL-

2 treatment is affecting only the output and/or survival of thymic-derived naïve Tregs but not their

differentiation towards HLA-II$^+$ effector Tregs. Furthermore, we also replicated the transient IL-

2-induced increase in the frequency of naïve Tregs by measuring the naïve:memory Treg ratio at

Day 27 by FACS in all 18 DILfrequency participants treated with the 3-day interval dosing

schedule (**Supplementary Fig. 9a-c**). We found good concordance between FACS and single-cell

data on the frequency of naïve and memory Tregs as well as their ratios (**Supplementary Fig.**

9d,e). To confirm the characterisation of Treg subsets obtained through the single-cell multiomics

analysis, we next assessed the protein expression of FOXP3 and HELIOS by FACS in our single

and multiple dosing replication cohorts. In agreement with the multiomics analysis, we found a

selective decrease in the relative proportion of CD45RA$^-$ FOXP3$^-$HELIOS$^-$ cells within

CD127^{low}CD25^{hi} T cells in both cohorts in response to iLD-IL-2 (**Supplementary Fig. 10a-c**).

These results translated into a consistent increase in the frequency of both CD4$^+$CD25^{hi} FOXP3$^+$

Treg subsets and a concomitant reduction in $CD4^+CD25^{hi}$ $FOXP3^-HELIOS^-$ Teffs

(**Supplementary Fig. 10d,e**).

In addition to the conventional $CD25^{hi}$ $FOXP3^+$ Treg subsets, we have recently shown that a subset

of $CD25^{-/low}$ $FOXP3^+$ T cells are increased in patients with autoimmune diseases[37]. We found no

substantial change in the frequency of $CD25^{-/low}$ $FOXP3^+$ T cells (defined as cells with >=1 copy

of FOXP3 within the $CD4^+CD25^{-/low}$ Tconv gate; **Supplementary Fig. 11a,b**). We replicated

these results using a FACS approach to vastly increase the number of characterised $CD25^{-/low}$

$FOXP3^+$ T cells. In agreement with the multiomics analysis we found no change in the frequency

of this rare subset in either the single or multiple dosing cohorts (**Supplementary Fig.11c-g**).

However, we noted a small reduction in the frequency of $CD25^{-/low}$ $FOXP3^+$ T cells at Day 27 by

both methods, suggesting that iLD-IL-2 may restore the CD25 expression in these cells.

IL-21-producing T cells are reduced by iLD-IL-2 treatment

Among the identified $CD25^+$ $FOXP3^-HELIOS^-$ Teff clusters within the sorted $CD127^{low}CD25^{hi}$

Treg cells, we noted an IL-2-induced reduction of a subset with a marked T follicular helper (T_{FH})

cell profile, including the expression of canonical T_{FH} receptors CXCR5, PD-1 and ICOS, and the

transcription factor *MAF* ($CD25^{hi}$ T_{FH}, cluster 8; **Supplementary Figs. 4a** and **6a**). Although

differentiated T_{FH} cells are rare in blood, within cells sorted from the $CD25^{-/low}$ Tconv gate, we

were able to characterise an analogous heterogeneous cluster of central memory (T_{CM}) $CXCR5^+$

cells (cluster 1; **Supplementary Fig. 7a-c**), which is known to be enriched with circulating

precursors of T_{FH} cells. Upon *in vitro* stimulation, which elicited the expression of the classical

T_{FH} cytokine IL-21, we obtained a better discrimination of the T_{FH} clusters. This led to improved

differentiation of a cluster of $CXCR5^+$ T_{CM} cells (cluster 2) and a cluster of $CXCR5^{low}$ $IL-21^+$ T

cells (cluster 6) that was reduced with IL-2 dosing (**Supplementary Fig. 7d-f**). In addition, within

the $CD127^{low}CD25^{hi}$ Treg gate, *in vitro* stimulation allowed the stratification of the activated

$CD25^+$ T_{FH} cells into two separate clusters (cluster 10 and 11) based on their expression of IL-21

that were both reduced by iLD-IL-2 treatment (**Supplementary Fig. 6b**). We note that a related

cluster of $FOXP3^+$ T follicular regulatory cells (T_{FR}, cluster 11 in unstimulated cells) which, in

addition to the T_{FH} signature, also featured a distinct Treg transcriptional profile as well as the

upregulation of *POU2AF1* and *CCR9*, was not altered by iLD-IL-2 treatment (**Supplementary**

Fig. 6a).

Next, we compared the transcriptional profile of the four identified T_{FH}-like clusters marked by

the specific upregulation of IL-21 expression. We identified a continuum of T_{FH} cell differentiation

among these clusters, with the CD25$^+$IL-21$^+$ T_{FH} subset representing the terminal stage of

maturation in blood, as illustrated by their classical T_{FH} profile and increased IL-21 production

(**Fig. 3a**). Analysis of the co-expression of CXCR5 and IL-21 revealed that IL-21 was

preferentially expressed within the CXCR5$^+$ cells (**Fig. 3b**). The exception was in the CXCR5^{low}

IL-21$^+$ cluster, where approximately 50% of the IL-21$^+$ cells were also CXCR5^{low}. These data

suggest that our single-cell multiomics approach allows us to specifically identify the more

differentiated IL-21-producing T cells in this cluster, with a phenotype resembling the CXCR5^{low}

PD-1^{hi} circulating T peripheral helper (T_{PH}) cells that have been previously shown to be increased

in T1D patients[23]. Furthermore, we found similar profiles between the CXCR5$^+$ T_{CM} and the

CD25$^+$ T_{FH} clusters sorted from the CD25$^{-/low}$ Tconv and CD25$^+$ Treg gates, respectively, with the

latter likely representing an earlier stage of T_{FH}-cell differentiation. In agreement with this shared

identity and developmental stage, the CXCR5$^+$ T_{CM} and CD25$^+$ T_{FH} subsets displayed largely

overlapping embeddings among all stimulated CD4$^+$ T cells (**Fig. 3c,d**). In contrast to these three

conventional T_{FH}-like subsets, which seem to share a similar differentiation pathway, the

CXCR5^{low}IL-21$^+$ CD25$^{-/low}$ Teff cluster represented a much more heterogeneous cluster with a

scattered clustering profile and increased IL-21 production (**Fig. 3c,d**).

To better discriminate the effect of IL-2 on the differentiation of IL-21-producing cells, we then

stratified the cells in these four T clusters according to their expression of IL-21 to define activated

T_{FH} profiles (**Fig. 3e**). Consistent with the results from the differential abundance analysis

(**Supplementary Figs. 6b** and **7e**), we found evidence for a reduction in the relative proportion of

IL-21$^+$ cells at Day 27 in the two subsets with higher frequencies of IL-21$^+$ cells (**Fig. 3f**).

Furthermore, pseudo-time analysis in total stimulated CD4$^+$ T cells revealed a similar trajectory of

T_{FH} cell differentiation characterised by the acquisition of an activated T_{FH} phenotype and

production of IL-21 (**Supplementary Fig. 8e-g**). In contrast with the FOXP3$^+$ Treg trajectory,

iLD-IL-2 was found to impair this differentiation trajectory, as illustrated by the reduced pseudo-

time distribution at Day 27 among cells from the more differentiated CD25$^+$IL-21$^+$ T_{FH} subset

(**Supplementary Fig. 8h**). These results further support a broader, previously uncharacterized, effect of iLD-IL-2 immunotherapy in potentially inhibiting the differentiation of IL-21-producing cells. In addition to the reduction of IL-21-producing cells, we also obtained some evidence (FDR-adjusted $P = 0.096$) for the reduction of another subset marked by the expression of many pro-inflammatory cytokines, including GM-CSF, IL-21 and IL-2, as well as the classical type-2 inflammatory cytokines IL-4 and IL-13 (CD25$^+$ T$_{H2}$ T$_{EM}$, cluster 6; **Supplementary Figs. 4b** and **6b**).

Effects of iLD-IL-2 on CD8$^+$ T and CD56$^+$ NK cells

In the CD8$^+$ T cell compartment, differential abundance analysis revealed no discernible differences in the relative composition of the conventional αβ CD8$^+$ T cell subsets after IL-2 treatment. However, we identified a previously uncharacterised reduction of two subsets of innate-like CD8$^+$ T cells, including mucosal-associated invariant T cells (MAIT; cluster 4) and V$_{\gamma 9}$V$_{\delta 2}$ T cells (cluster 9; **Fig. 4a,b** and **Supplementary Fig. 12**). In contrast to the IL-2 induced alterations in the CD4$^+$ T cell compartment, the reduction of circulating MAIT and V$_{\gamma 9}$V$_{\delta 2}$ T cells was more long-lived and there was still evidence of a reduced frequency in blood one month after the last dose of IL-2 (**Fig. 4c**).

Finally, in the CD56$^+$ NK cell compartment, despite the lower level of functional heterogeneity and differentiation (**Fig. 4d,e**), we found that the increased frequency of CD56^{br} NK cells after IL-2 treatment, was driven particularly by an increased relative proportion of an activated HLA-II$^+$ subset (**Fig. 4f**). By contrast we found no alterations in the relative composition of CD56^{dim} subsets (**Fig. 4g** and **Supplementary Fig. 13**). Consistent with activation phenotype and increased expression of CD56 on CD56^{br} NK cells after treatment, we observed a reduced frequency of contaminating CD56^{dim} and CD56^{br} NK cells sorted from the CD56^{br} and CD56^{dim} NK cell gates, respectively at Day 27 (**Fig. 4f,g**). The alterations in the CD56^{br} NK cells were also transient and were not maintained one month after treatment (**Supplementary Fig. 13b,c**).

Interval low-dose IL-2 immunotherapy induces a systemic and long-lasting anti-inflammatory gene expression signature

We next investigated whether, in addition to cellular composition alterations, we could detect IL-2-induced gene expression changes. On Day 27, we identified 40 genes that are differentially expressed in one or more subsets of unstimulated and stimulated cells (**Fig. 5a-c**). Consistent with previous flow cytometry analyses[19], CD25 was strongly upregulated on Tregs on Day 27. The differential expressed genes were mostly restricted to the more IL-2-sensitive CD127^lowCD25^hi Treg and CD56^br NK cell subsets and could be broadly categorised into CD4^+ Treg and CD56^br NK cell signature genes, reflecting the relative increased proportion of both subsets after iLD-IL-2 treatment, as well as the identified reduction in actively dividing CD56^br NK cells (**Supplementary Fig. 3b**). Cycling cells were not present in the stimulated cell populations, potentially due to the preferential sensitivity of cycling cells to apoptosis following activation.

Contrary to the differential expression on Day 27, which was observed exclusively in the IL-2-sensitive Treg and CD56^br subsets, differential expression on Day 55, one month after the last IL-2 injection, was widespread and displayed a consistent pattern in all five assessed immune subsets (**Fig. 6a** and **Supplementary Fig. 14a,b**). These findings indicate that our iLD-IL-2 dosing regimen induces a shared Day 55 gene expression signature in different cell types, which featured most prominently the upregulation of Cytokine Inducible SH2 Containing Protein (*CISH*), a gene encoding a well-characterised negative regulator of cytokine signalling, and the downregulation of Amphiregulin (*AREG*), a secreted TNF-inducible protein with pleiotropic roles in inflammation[38]. We also noted an enrichment of genes associated with cytokine signalling, most notably in the tumour necrosis factor (TNF) signalling pathway, which in addition to *CISH* and *AREG*, also included *TNFSF14*, *TNFSF10*, *STAT1*, *SGK1*, *NFKBIZ*, *NFKBIA*, *DUSP2*, *DUSP4*, *DUSP5*, *RGS1* and *TNFAIP3* (**Fig. 6a**). Furthermore, we observed a downregulation of several TNF-induced genes that play a central role in curtailing TNF signalling, including the inhibitors of NFκB, *NFKBIZ* and *NFKBIA*, *RGS1*, *TNFAIP3* and *AREG*. Consistent with this observation, Oncostatin M (*OSM*), a pro-inflammatory cytokine shown to be increased in inflammatory bowel disease patients with poor response to anti-TNF therapy[39], was also downregulated by iLD-IL-2. Increased expression of *TNFSF14*, which encodes LIGHT, is notable since decreased expression is associated with higher susceptibility to multiple sclerosis[40] and in a mouse model of multiple

sclerosis, LIGHT expression in the brain limits disease severity[41]. The widespread detection of this

signature in all five T and NK cell populations assessed in this study suggests that this effect is not

driven by IL-2 signalling directly but is likely the result of the sustained cellular changes induced

by iLD-IL-2 immunotherapy.

Although this Day 55 expression signature was detected in 11 of the 12 participants with Day 55

data, we observed heterogeneity among participants for the expression levels of the same genes on

Day 27 (**Fig. 6b**). Some participants exhibited concordant expression changes on Day 27 and Day

5, compared to Day 0, while others showed discordant expression profiles, with *CISH* being

downregulated and *AREG* upregulated on Day 27. Moreover, by principal component analysis

(PCA), we found that this concordant-discordant axis, captured by the first principal component

(PC1), was able to largely explain the inter-individual heterogeneity of Day 55 signature genes on

Day 27 and appeared to be associated with IL-2 dose (**Supplementary Fig. 14c**). Considering this,

we derived a linear score to quantify the changes in the Day 55 signature for each participant,

referred to as the Day 55 signature score, with higher scores reflecting higher expression of

signature genes upregulated on Day 55 (e.g. *CISH*), and lower expression of signature genes

downregulated on Day 55 (e.g. *AREG*). As expected, the Day 55 signature score showed

considerable inter-individual variation (**Fig. 6c**) that was consistent across different cell types

(**Supplementary Fig. 14d**). This enabled us to correlate changes in signature score, which

indicated the direction and amplitude of the modulation of Day 55 genes, with IL-2 dose level. We

confirmed that participants receiving higher doses of IL-2 were more likely to have increased

signature scores on Day 27 and Day 55 compared the baseline, indicating concordant expression

changes, whilst participants receiving lower doses tended to show discordant changes (**Fig. 6d,e**).

The dose-dependence of the Day 55 signature reached statistical significance only when

comparing to the participant-specific baseline, but not when inspecting the cross-sectional data at

each time point (**Supplementary Fig. 14e**). This underscores the importance of our longitudinal

study design that enhanced our statistical power to identify differential expression patterns.

Long-lived iLD-IL-2 gene expression alteration is inversely modulated in COVID-19 patients

and is progressively induced after the onset of symptoms

To extend the support for the existence of the Day 55 gene expression signature, we sought independent evidence of a similar transcriptional response with another immune challenge. Recently, the Oxford COVID-19 Multi-omics Blood Atlas (COMBAT) study[42] has generated a large single-cell dataset illustrating the changes in blood induced by COVID-19 infection. We found a reverse regulation in all immune populations of the 41 identified IL-2 regulated Day 55 signature genes, including a marked downregulation of *CISH* and upregulation of *AREG* in COVID-19 patients (**Fig. 7A**). This finding was replicated in an independent cohort of convalescent COVID-19 patients (INCOV)[43]. In both cohorts, we observed a progressive reduction of the Day 55 gene expression signature, which was particularly pronounced for the first 2-3 weeks after the onset of symptoms (**Fig. 7b,c**). In the INCOV cohort, follow-up samples taken several months after initial symptoms revealed signs of a slow recovery towards the pre-COVID-19 baseline. (**Fig. 7c**). This progressive induction of the Day 55 signature genes was observed in all COVID-19 disease severity groups and was consistent in all immune populations (**Supplementary Fig. 15**).

In the COMBAT study[36], a multiparametric COVID-19-induced gene expression signature, designated as Component 187, featured the differential expression of several Day 55 iLD-IL-2 signature genes, including *CISH* and *AREG*. Of the 1,419 genes contributing to the COVID-19 Component 187, 77 were present in our transcriptional panel. We found that virtually all signature genes upregulated on Day 55 had negative loading scores in the COVID-19 Component 187, and vice versa (**Fig. 7d**), indicating a strong inverse correlation between the differential gene expression induced by IL-2 treatment and COVID-19. In the COMBAT study, Component 187 belonged to Cluster 3, a cluster of similar gene expression signatures associated with all severity groups of COVID-19 patients. We found that Cluster 3 showed the strongest enrichment of the Day 55 Signature genes, compared to all other reported clusters (**Fig. 7e**). Furthermore, the dynamics of Component 187 over time were similar to that of the Day 55 Signature, though in the opposite direction (**Fig. 7f**), implying that the set point of a homeostatic cellular network is altered in opposing directions by LD-IL-2 immunotherapy and COVID-19.

Discussion

Our findings not only extend previous studies[15–17,28] but also provide new insight into the
mechanism of action of LD-IL-2 that has practical implications for its clinical use: firstly, we show
that LD-IL-2 administered every three days for a period of one month is able to selectively increase
the frequency and number of thymic-derived FOXP3+HELIOS+ Tregs in all 18 study participants
analysed, while showing no detectable impact on the expansion or activation of conventional
effector T or CD56^{dim} NK cells. We observed a particularly pronounced increase in the frequency
of naïve FOXP3+HELIOS+ Tregs after iLD-IL-2 therapy, indicating that the Treg increases are
caused by an increased representation of thymic-derived Tregs, and not the proliferation of
peripherally-induced Tregs. These findings are consistent with the increased clonal diversity in T
cells following an escalating LD-IL-2 regimen in graft-versus-host disease patients[44,45]. Secondly,
we also noted that our iLD-IL-2 schedule did not induce a detectable cytotoxic gene expression
signature in any T cell subset, indicating that among T cells iLD-IL-2 has a Treg-specific effect
and does not lead to the activation of a pro-inflammatory response. In addition to Tregs, the CD56^{br}
NK cell population is also probably contributing to the overall anti-inflammatory effects of iLD-
IL-2, in an immunoregulatory role, as previously described[46,47]. Thirdly, iLD-IL-2 was able to
reduce IL-21-producing T cells, possibly by antagonizing their differentiation. IL-2 signalling has
been shown to inhibit the differentiation of T$_{FH}$ cells *in vivo* in mice[48], and in an *in vitro* model in
humans[49]. Consistent with these findings, LD-IL-2 has been shown to decrease the frequency of
T$_{FH}$ cells, as defined by cell surface markers[50], as well as the frequency of marginal zone B cells[29]
in SLE patients, supporting a role in the regulation of germinal centre reactions. Our results extend
these findings to T1D and demonstrate a specific effect of iLD-IL-2 treatment in reducing
pathogenic IL-21-producing CXCR5+ T$_{FH}$ cells as well as IL-21-producing CXCR5^{low} T cells.
Previously, we have shown that a two-fold increase in IL-2, but not IL-21, was responsible for the
protective effect conferred by the *Idd3* locus (containing *IL2* and *IL21*) in the nonobese diabetic
(NOD) mouse model of T1D[13], and independently that a reduction in IL-21 correlated with
increased IL-2[51]. In humans, IL-21 has been implicated in the pathogenesis of several autoimmune
diseases[52,53], particularly T1D[21–23]. Together, these observations lend further support for the use of
iLD-IL-2 in T1D as well as in other diseases associated with increased IL-21 production, such as
systemic lupus erythematosus, rheumatoid arthritis, and psoriasis. In support of this therapeutic

strategy, an anti-IL-21 monoclonal antibody in combination with liraglutide showed promising

results in preserving beta-cell function[24]. Of note, we observed no evidence for the alteration of

the frequency of FOXP3$^+$ T$_{FR}$ cells, which has been previously shown to play a role in the

regulation of T$_{FH}$ cells and the germinal centre reaction[54,55].

We also observed a decrease in circulating innate-like CD8$^+$ MAIT and V$_{\gamma9}$V$_{\delta2}$ T cell subsets

during treatment and one month after. Since these cells function in anti-viral and anti-bacterial

defence[56], our findings suggest a role of IL-2 immunotherapy in the recruitment of MAIT and

V$_{\gamma9}$V$_{\delta2}$ T cells to tissues following treatment, thereby increasing defence against viral and bacterial

infections[57]. This could provide a mechanism for the observed decreased incidence of viral

infections in SLE patients undergoing LD-IL-2 immunotherapy[58].

The cellular alterations induced by iLD-IL-2 treatment led to the establishment of a long-lived

gene expression signature in all assessed immune populations, which suggest a novel

immunoregulatory mechanism of iLD-IL-2. Although the effects of this signature are not yet

understood, it is marked by the distinct upregulation of *CISH*, a well-characterised negative

regulator of cytokine signalling whose expression is known to be induced by IL-2, as well as other

cytokines, signalling through the activation of STAT5[59]. In contrast, among the downregulated

genes, we observed several negative regulators of an inflammatory response at Day 55, including

key TNF-induced genes such as *TNFAIP3*, *RGS1* and *AREG*, suggesting that iLD-IL-2 can

decrease the homeostatic levels of TNF for at least one month after the cessation of dosing. Support

for the existence of the iLD-IL2-induced long-lived gene expression signature was obtained from

analysis of the Oxford COMBAT dataset[42], where we detected the modulation of the same genes,

but showing consistent opposite direction of expression following the onset of COVID-19

symptoms. We replicated this signature in a large longitudinal cohort of convalescent COVID-19

patients[43], which demonstrated a progressive induction of these genes that was particularly

pronounced in the first two weeks after onset of symptoms. This altered expression profile was

consistently sustained for up to 5 months, evidencing the longevity of this immune dysregulation

in COVID-19 patients. One possible explanation for the longevity of the signature is that TNF and

IL-2 are among the cytokines known to bind to the extracellular matrix[33–36] and that the retention

of the cytokines within tissues extends far beyond their initial increases[60]. The establishment of

the Day 55 IL-2 signature is dose-dependent at Day 27, likely reflecting a dose-dependent

accumulation of injected IL-2 on the extracellular matrix within the interstitial space following
subcutaneous dosing. A long-lasting immune alteration that also possibly reflects a continuing
inflammatory stimulus or long-lived pro-inflammatory cytokines on the extracellular matrix has
been reported in mild COVID-19 patients, with infection inducing a pro-inflammatory response in
monocyte-derived macrophages that continues to be detected 3-5 months following SARS-CoV-2
infection[61]. In a separate study, pro-inflammatory markers such as IL-8 and sTIM-3 were still
elevated four months after the cessation of COVID-19 symptoms in patients having had mild or
moderate disease, but the increases resolved eight months post-infection except in patients with
long COVID[62].

We hypothesise that the balance between pro- and anti-inflammatory cytokines bound to the
extracellular matrix provides a regulatory mechanism to control immune responses. Circulating
immune cells can constantly integrate this information through a combination of cell-type specific
receptors. Under homeostatic conditions this provides a dynamic buffer system preventing
excessive (or potentially chronic) immune activation. A perturbation of this balance via either
sustained regulatory (e.g. iLD-IL-2 immunotherapy) or inflammatory (e.g. SARS-CoV-2
infection) environment can alter the composition of the soluble mediators contained in the
extracellular matrix, and consequently affect the interaction between the immune system and the
local environment, leading to the remodelling of their transcriptional profile and an alteration of
their threshold for further stimulation. Such a complex system is likely critical not only to prolong
the biological activity of key immune mediators such as TNF and IL-2, but also to control site
specificity to prevent improper signalling in the wrong physiological context. These findings are
also consistent with our observation that pro-inflammatory gene expression is progressively
induced after infection, and that it could contribute to the long-lasting systemic alterations
associated with the persistence of clinical manifestations in long COVID patients.

A limitation of this study is that we were not able to elucidate the exact mechanism underpinning
the induction of the identified long-lived gene expression signature and how this is regulated by
iLD-IL-2 or COVID-19. Although we show that iLD-IL-2 can induce this signature, it is certainly
not the only responsible factor, as a reversed expression can also be induced in a completely
different pathophysiological context such as COVID-19. Furthermore, markers of disease activity
and progression are limited in T1D and were not collected for the DILfrequency patients, which

precludes the analysis of how they are associated with these gene expression alterations. A more

comprehensive investigation of these questions will need to be performed in an appropriate follow

up cohort such as the recently completed Interleukin-2 Therapy of Autoimmunity in Diabetes

(ITAD) trial[63]. The findings from this study will inform the design of suitable follow up

experiments in this and other studies of iLD-IL-2 in multiple diseases and will be critical to better

understand both the longevity of the signature and how it is associated with clinical outcomes.

Another limitation is that the interpretation of the results may be dependent on our specific iLD-

IL-2 dosing regimen. Although it is likely that most regimens will induce very similar results, it

will be important to validate these findings in different dosing schedules. Given the diverse range

of conditions where LD-IL-2 immunotherapy is being trialled, it is critical to better understand

how dosing regimen affects the drug's mechanism of action, and to tailor it to the disease-specific

applications, including when best to administer IL-2 during the course of standard care or as a way

of maintaining the clinical benefits of ongoing treatments[64], for example, in the use of anti-CD3

(teplizumab) to treat and prevent T1D[65].

Taken together, our findings provide a better understanding of the mechanism of action of LD-IL-

2 immunotherapy. In the past there have been concerns over the very short half-life of recombinant

IL-2 *in vivo* and that NK cell expansion might be detrimental, which have led to the development

of genetically-modified IL-2 muteins with increased half-life and preferential binding to the high-

affinity trimeric IL-2 receptor in order to reduce CD56[br] NK cell stimulation. Our results

demonstrating a long-lived gene expression signature associated with potential anti-inflammatory

effects, detectable one month after the end of aldesleukin treatment, alleviate some of these

concerns and support the therapeutic potential of IL-2 that is not engineered for longer *in vivo* half-

life or preferential binding to the high affinity IL-2 receptor, given intermittently and at low doses.

Our study adds to the good track record of using low-dose recombinant IL-2 and confirms its very

strong safety profile, which is critical for the potential long-term use of LD-IL-2 immunotherapy

for diseases such as T1D in which the target patient population will consist mainly of children,

including the possible future use of iLD-IL-2 treatment in the prevention of T1D diagnosis, as

demonstrated in recent teplizumab trials[65] and for T1D treatment with other monoclonal antibodies

such as golimumab (anti-TNF)[66,67]. Additionally, iLD-IL-2 treatment could be trialled in

recovering COVID-19 patients, after acute inflammation has been resolved, to determine if such

treatment hastens the restoration of normal immune homeostasis and perhaps reduce the

occurrence of long COVID complications.

Methods

The study was performed in accordance with the guidelines for good clinical practice and the

Declaration of Helsinki. Study participants included T1D patients enrolled in two single centre

mechanistic studies of low-dose recombinant IL-2 (aldesleukin) immunotherapy: (i) the Adaptive

study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D), a non-randomised single

IL-2 dosing study20; and (ii) the Adaptive study of IL-2 dose frequency on regulatory T cells in

type 1 diabetes (DILfrequency), a response-adaptive trial of repeated doses of IL-2 administered

using an interval dosing approach21. Approval was obtained from the Health Research

Authority, National Research Ethics Service (13/EE/0020 and 14/EE/1057, for the DILT1D and

DILfrequency studies, respectively), London, United Kingdom. The trials were registered at the

International Standard Randomised Controlled Trial Number Register (ISRCTN27852285 and

ISRCTN40319192) and ClinicalTrials.gov (NCT01827735 and NCT02265809). The study

protocols were published in advance of the completion and final analysis of the trials[68,69]. All

participants provided written informed consent prior to their participation in the studies.

Study design and participants

Study participants comprised 18 T1D patients enrolled in the DILfrequency study[19]. All 18 study

participants, who were all adult patients diagnosed with T1D over 60 months before recruitment

into the study, were selected from the 3-day interval group and were treated with IL-2 with doses

ranging from 0.2 to 0.47×10^6 IU/m^2.

FACS-based replication of the single-cell multiomics findings was performed in two follow-up

cohorts: (i) a single-dosing cohort, comprising 6 DILT1D patients[18] treated with a single dose of

IL-2 ranging from 0.6 to 1.5 x 10^6 IU/m^2; and (ii) a multiple dosing cohort, comprising 5

DILfrequency patients from the three-day dosing regimen, treated with IL-2 doses ranging from

0.2 to 0.32×10^6 IU/m^2. Study participants' characteristics and immune profiling at baseline are

summarised in **Supplementary Table 1**.

Flow cytometry

Flow cytometric characterisation of fresh whole-blood samples from the DILfrequency study participants was performed at each visit within 4 h of phlebotomy, as previously described[20]. Briefly, 150 μl whole blood were incubated for 45 min at room temperature with fluorochrome-conjugated antibodies (**Supplementary Table 2, 2nd panel**). Red blood cells were then lysed (BD FACS Lysing solution). The absolute number of the main lymphocyte populations, including CD4$^+$ T, CD8$^+$ T and CD56$^+$ NK cells, was assessed using a whole-blood BD Multitest 6-Color TBNK assay using BD Trucount Tubes according to the manufacturers' instructions (BD Biosciences) at each visit. Absolute numbers of CD4$^+$ Tregs and Tconvs, and CD56^{br} and CD56^{dim} NK cells were derived by multiplying the absolute number of CD4$^+$T cells and CD56$^+$ NK cells by the appropriate percentages derived from the panel described above.

For the intracellular immunostainings, cryopreserved PBMCs were thawed at 37°C and resuspended drop-by-drop in X-VIVO 15 (Lonza) with 1% heat-inactivated, filtered human AB serum (Sigma). PBMC samples were selected from 10 visits (Days 0, 1, 2, 3, 4, 5, 6, 9, 14 and 28) from each patient from the single-dosing and 4 visits (Days 0, 3, 27 and 55) for the multiple dosing cohort. PBMCs were then washed in PBS, incubated with Fixable Viability Dye eFluor 780 (eBioscience) for 15 min at 4°C and stained with fluorochrome-conjugated antibodies against surface-expressed markers (**Supplementary Table 2)** for 45 min at 4ºC. Fixation and permeabilisation was performed using the FOXP3 Fix/Perm Buffer Set (eBioscience) according to the manufacturer's instructions, and cells were then stained with fluorochrome-conjugated antibodies against intracellular markers (**Supplementary Table 2)** for 1 h at room temperature.

Immunostained samples were acquired on a BD Fortessa (BD Biosciences) flow cytometer with FACSDiva software (BD Biosciences) and analysed using FlowJo (Tree Star, Inc.). Information for all fluorochrome-conjugated antibody panels used in this study is provided in Supplementary Table 2.

***In vitro* Treg suppression assay**

A total of 12 DILfrequency participants were selected for this analysis, including nine participants that were also included in the single-cell analyses. For each participant, cells sampled from three time points were used: Day 0, Day 24 and Day 55. Cryopreserved PBMCs were thawed as

described above and stained with a cocktail of monoclonal antibodies (**Supplementary Table 2**)
for cell sorting. Suppression assays were established in V-bottom 96-well plates by sorting 500
CD4$^+$CD25$^{-/lo}$CD127$^+$ effector T cells (Teffs) in the presence or absence of
CD4$^+$CD25^{high}CD127^{low} Tregs at various ratios (Treg:Teff 0:1, 1:4, 1:2 and 1:1) with 1×10^3
CD19$^+$ B cells, using the BD FACSAria III flow cytometer automated cell deposition unit (BD
Biosciences). Cells were sorted into in 150 µl X-VIVO 15 supplemented with Penicillin-
Streptomycin-Fungizone (Gibco) and 10% heat-inactivated, filtered human AB sera, stimulated
with PHA (4 µg/ml; Alere) and incubated at 37°C, 5% CO$_2$, for 5 days. Proliferation was assessed
by the addition of 0.5 µCi/well [3H] thymidine (PerkinElmer) for the final 20 h of co-culture.
Conditions were run in 5 replicates, and proliferation readings (counts per minute [CPM])
averaged. Two samples with averaged proliferation less than 1,000 CPM from the Teff wells alone
were excluded from the analysis. The percentage suppression in each culture was calculated using
the following formula: percent suppression = 100 − [(CPM in the presence of Tregs ÷ CPM in the
absence of Tregs) × 100]. All time points from a participant were analysed concurrently.

Single-cell multiomics: cell preparation and capture

Single-cell multiomics profiling was performed using the BD Rhapsody system on PBMC aliquots
from 13 of the DILfrequency participants treated with the 3-day interval dosing schedule
(**Supplementary Table 1**) collected at the baseline visit (Day 0), 3 days after the last dose of IL-
2, immediately prior to the last IL-2 infusion of the dosing phase (Day 27) and one month after the
last dose of IL-2 (Day 55). Cryopreserved PBMCs were thawed at 37°C and resuspended drop-
by-drop in X-VIVO 15 with 1% heat-inactivated, filtered human AB serum. After washing in PBS,
cells were incubated with Fixable Viability Dye eFluor 780 (eBioscience) for 10 min at room
temperature, washed with cold PBS + 2% FBS and incubated for 30 min at 4ºC with fluorochrome-
conjugated antibodies for sorting (**Supplementary Table 2**). Cells were then washed two times
and resuspended in cold PBS + 1% FBS for cell sorting at 4ºC in a BD FACSAria Fusion sorter
(BD Biosciences). The following T and NK cell subsets were sorted from each participant at each
visit: (i) CD3$^-$CD56^{hi} (CD56^{br} NK; (ii) CD3$^-$CD56$^+$ (CD56^{dim} NK; (iii) CD3$^+$CD8$^+$ (CD8$^+$ T); (iv)
CD3$^+$CD4$^+$ CD25$^{-/low}$ (CD4$^+$ Tconv); and (v) CD3$^+$CD4$^+$ CD127^{low}CD25^{hi} (CD4$^+$ Treg). We

aimed to sort a total of 130,000 cells for the Day 0 and Day 55 visits and 160,000 for the Day 27

visit, with the following proportion of each of the sorted cell populations: 30% CD4$^+$ Treg; 25%

CD4$^+$ Tconv and CD8$^+$ T; 12% CD56^{br} NK and 8% CD56^{dim} NK cells.

Following cell sorting, each sorted subset was labelled with the respective sample barcoding

antibody (sample multiplexing kit; BD Biosciences) for 20 min at 4ºC to allow for the

identification of the sorting gate and visit of each captured single cell. To minimise day-to-day

variation, we processed the three PBMC samples corresponding to the three visits from each

participant on the same day. As the number of barcoded oligo-conjugated antibodies available in

the kit was less than the total number of sorted subsets, we combined the CD4$^+$ Treg and CD56^{dim}

NK cells as well as the CD4$^+$ Tconv and CD56^{br} NK cells from each visit and labelled the pooled

cells with the same barcode. These combined subsets were chosen for their highly differentiated

transcriptional and proteomics profile, which allowed robust separation of the respective original

subsets at the analysis stage. Cells were then washed three times with BD Sample Buffer (BD

Biosciences) at 4ºC to remove any residual unbound barcoding antibody and then pooled together

for downstream processing.

To profile unstimulated cells, half of the pooled cells volume (corresponding to ~210,000 cells)

were initially incubated at 4ºC for 5 min with human Fc block (BD Biosciences) and then for a

further 45 min with a master mix of 65 oligo-conjugated AbSeq antibodies (BD Bioscience;

Supplementary Table 2). Cells were then washed three times with BD Sample Buffer at 4ºC to

remove residual unbound oligo-conjugated AbSeq antibodies, resuspended in 500 ul cold BD

Sample buffer and filtered through a sterile 50 μm Filcon cup-type filter (BD Biosciences) for cell

counting. Samples were then resuspended in 620 μl of cold BD sample buffer at a concentration

of 40 cells/μl - for an estimated capture rate of ~20,000 single-cells / cartridge - and immediately

loaded on two BD Rhapsody cartridges (BD Biosciences) for single-cell capture.

For *in vitro* stimulation, the remaining volume from the pooled cells was washed at 4ºC and

resuspended in X-VIVO 15 + 10% heat-inactivated, filtered human AB serum at a final

concentration of 2×10^6 cells/ml. A volume of 100 μl (~200,000 cells) was then incubated in one

well of a round-bottom 96-well plate at 37ºC for 90 minutes with a PMA and ionomycin cell

stimulation cocktail (eBioscience), in the absence of protein transport inhibitors. Cells were

harvested into a FACS tube, washed with PBS + 2% FBS and processed for cell capture, as detailed

above for the unstimulated cells.

Single-cell multiomics: cDNA library preparation and sequencing

Single-cell capture, and cDNA library preparation was performed using the BD Rhapsody Express

single-cell analysis system (BD Biosciences), according to the manufacturer's instructions. cDNA

was initially amplified for 11 cycles (PCR1) using the pre-designed Human T-cell Expression

primer panel (BD Biosciences) containing 259 primer pairs, together with a custom designed

primer panel containing 306 primer pairs (BD Biosciences), described previously[20]. A total of 565

primer pairs targeting 534 different genes were targeted for amplification with this targeted panel

(**Supplementary Table 2**).

The resulting PCR1 products were purified using AMPure XP magnetic beads (Beckman Coulter)

and the respective mRNA and AbSeq/sample tag products were separated based on size selection,

using different bead ratios (0.7× and 1.2×, respectively). The purified mRNA and sample tag PCR1

products were further amplified (10 cycles) using a nested PCR approach and the resulting PCR2

products purified by size selection (0.8× and 1.2× for the mRNA and sample tag libraries,

respectively). The concentration, size and integrity of the resulting PCR products was assessed

using both Qubit (High Sensitivity dsDNA kit; Thermo Fisher) and the Agilent 4200 Tapestation

system (Agilent). The final products were normalised to 2.5 ng/µl (mRNA), 1.1 ng/µl (sample tag)

and 0.35 ng/µl (AbSeq) and underwent a final round of amplification (six cycles for mRNA and

sample tag and 7 cycles for AbSeq) using indexes for Illumina sequencing to prepare the final

libraries. Final libraries were quantified using Qubit and Agilent Tapestation and pooled

(~29/67/4% mRNA/AbSeq/sample tag ratio) to achieve a final concentration of 5 nM. Final pooled

libraries were spiked with 15% PhiX control DNA to increase sequence complexity and sequenced

(150 bp paired-end) on a NovaSeq 6000 sequencer (Illumina).

Pre-processing of single-cell sequencing data

The single-cell sequencing reads were processed following instructions from BD Biosciences
described earlier[27], with slight modifications. First, low-quality read pairs were removed based on
read length, mean base quality score and highest single-nucleotide frequency. High-quality R1
reads were analysed to extract cell labels and unique molecular identifier (UMI) sequences. High-
quality R2 reads were aligned to the reference panel sequences using Bowtie2[70]. Reads having the
identical cell labels and UMI sequences and aligned to the same gene were collapsed into a single
molecule. To correct sequencing and PCR errors, the obtained counts were adjusted by a recursive
substitution error correction (RSEC) algorithm developed by BD Biosciences. The sampling time
point and sorting gate of origin of each cell were labelled using information from barcoded oligo-
conjugated antibodies. Cells without barcoding information were labelled as "tag N/A", and cells
with two or more barcodes were labelled as "multiplet". We note that sample barcoding and AbSeq
staining efficiency was compromised in $CD56^{br}$ NK cells. As the quality of the main mRNA library
was not affected by this technical issue, $CD56^{br}$ NK cells without barcoding information were
included in the quality control and clustering step, but excluded from subsequent analyses
dependent on sampling time point (see below). This led to a significant reduction in the number of
$CD56^{br}$ NK cells analysed and a concomitant reduction in statistical power to identify IL-2-induced
alterations. Nevertheless, we also note that our cell-enrichment strategy compensated for this cell
loss due to technical reasons and provided sufficient resolution to dissect the heterogeneity of the
rare population of $CD56^{+}$ NK cells.

Doublet scoring

Doublet scoring was performed on each sample separately using Scrublet[71]. Briefly, this method
simulates synthetic doublets by sampling pairs of cells and then scores each cell by its similarity
to the simulated doublets. For each sample, count matrices for RNA and AbSeq data were
concatenated and used as the input. The method was modified to exclude known multiplet-tagged
cells from the doublet simulation while retaining them for scoring. The doublet score was used to
help identify clusters of doublets in subsequent quality control stages.

Normalisation, integration, dimensionality reduction and clustering

Data normalisation was performed using Seurat[72]. The RNA count matrices were normalised by log normalisation. Specifically, the RNA counts for each cell were (i) divided by the total counts for that cell, (ii) multiplied by a scale factor of 10,000, and (iii) natural-log transformed after adding one pseudo count. The AbSeq counts for each cell were considered compositional and normalised by a centred log ratio transformation[73]. Normalised RNA and AbSeq expression matrices were then centred and scaled. Specifically, each feature was linearly regressed against selected latent variables including the number of RNA and AbSeq features, and the donor of origin, where appliable. The resulting residuals were mean-centred and divided by their standard deviations.

Integration of the scaled AbSeq expression matrices from different participants were performed using a combination of canonical correlation analysis (CCA) and identification of mutual nearest neighbours (MNNs), implemented in Seurat[72]. After integration was performed, the updated AbSeq expression matrices produced by the integration algorithm were used in subsequent dimensionality reduction and clustering.

Dimensionality reduction and clustering were performed using Seurat[72]. Specifically, principal components (PCs) were calculated separately for each assay using the top variable features of the scaled or integrated expression matrices, and a weighted nearest neighbour (WNN) graph as well as a weighted shared nearest neighbour (WSNN) graph were generated on the ten top PCs from each assay, unless otherwise specified. We used $k = 30$ nearest neighbours for each cell. Uniform Manifold Approximation and Projection (UMAP)[74] embeddings were then calculated based on the WNN graph. The Louvain algorithm[75] was applied to identify clusters of cells based on a WSNN graph, at the selected resolution level. Clusters with fewer than ten cells were removed. The resulting clusters were manually annotated based on marker genes and sorting gate information to elucidate cell types and label suspicious clusters.

Data quality control

The BD Rhapsody single-cell sequencing data generated in this study was processed through a pipeline consisting of multiple quality control steps as described below. Methodological details of each step are specified in previous sections. The single-cell sequencing data of each sample (i.e. the collection of stimulated and unstimulated cells for a single participant) were pre-processed to obtain two annotated count matrices (RNA and AbSeq). We performed data normalisation, dimensionality reduction and clustering for each sample. Specifically, 30 RNA principal components (PCs) and 30 AbSeq PCs were used to generate the WNN and WSNN graphs, and clustering was performed at resolution 0.5.

Within each sample, cells meeting one of the following criteria were removed: (1) cells that are labelled as "multiplet" or in clusters with high doublet scores; (2) cells labelled as "tag N/A", except those in clusters annotated as CD56^{br}; (3) cells in clusters with very low RNA counts and very low or very high AbSeq counts; (4) cells in clusters annotated as monocyte or B cell contamination; (5) cells labelled as DN T cells.

The filtered cells from each participant were merged according to the stimulation status into two datasets (unstimulated cells and *in vitro* stimulated cells). Both stimulated and unstimulated cells were then processed in the same way unless otherwise specified. We performed data normalisation, dimensionality reduction and clustering for each merged dataset. Specifically, clustering was performed at resolution 0.7 (unstimulated cells) or 1.5 (stimulated cells). Doublet clusters were manually annotated and removed. Data normalisation, dimensionality reduction and clustering were performed again. Specifically, clustering was performed at resolution 0.5.

Cells in each filtered dataset were subsequently partitioned into four major groups (CD4$^+$ Treg, CD4$^+$ Tconv, CD8+ T and CD56$^+$ NK cells) based on cluster annotations and sorting gates of origin. In addition, unstimulated cells in clusters marked by genes related to cell cycle were grouped as cycling cells. We chose to partition cycling cells into one separate group based on the following considerations: (i) cycling cells were relatively rare in numbers (0.72% of total unstimulated cells); (ii) cycling cells clusters had well-defined mRNA markers; (iii) The phenotypical differences between cycling cells and their non-cycling counterparts were potentially larger than the heterogeneity within each major cell populations.

After partitioning, doublet clusters were manually annotated and removed. Data normalisation,

dimensionality reduction, integration and clustering were performed in each group of partitioned

cells. Specifically, clustering was performed at resolution 0.5. Finally, data normalisation,

dimensionality reduction, and clustering were performed again.

Owing to the aforementioned technical limitations with AbSeq staining in CD56^{br} NK cells, AbSeq

data was not used in dimensionality reduction and clustering of NK cells. The following

resolutions were used for the final clustering: unstimulated Tregs, 0.6; unstimulated Tconvs, 0.5;

unstimulated CD8, 0.5; unstimulated NK, 0.3; unstimulated cycling cells, 0.5; stimulated Tregs,

0.5; stimulated Tconvs, 0.4; stimulated CD8: 0.5; stimulated NK: 0.5. The resulting partitioned

datasets were used for subsequent analyses. We note that one PBMC aliquot (corresponding to the

Day 55 visit of Participant 8) yielded very low cell numbers (N = 603 unstimulated and N = 67

stimulated cells) and displayed a compromised FACS staining profile. These cells were included

in quality control and clustering procedures but excluded from downstream analyses. All other 38

samples corresponding to 38 visits yielded the expected cell frequencies and numbers.

Single-cell proliferation scores

Single-cell proliferation scores were calculated using a previously described approach[76], which is

based on the average normalised expression levels of a pre-selected set of 11 mRNA features

related to cell cycle (*AURKB*, *HMGB2*, *HMMR*, *MCM4*, *MKI67*, *PCLAF*, *PCNA*, *TK1*, *TOP2A*,

TYMS, and *UBE2C*), subtracted by the aggregated expression of a control set of 50 randomly

selected mRNA features. The proliferation scores were used to identify two cycling clusters from

the 15 functional T and NK cell subsets identified in blood from the initial clustering

(**Supplementary Fig. 3a**). We noted that the distinct co-expression of these cell-cycle genes

present in our targeted transcriptional panel superseded more subtle functional differences and

aggregated all cycling T and NK cells into two respective clusters, regardless of their original

sorting gate. Given this lack of functional differentiation and to avoid the potential overwhelming

effect of these cell-cycle genes on the resulting clustering visualisation, we opted to separate these

cycling T and NK cells from the rest of the cells included in subsequent clustering steps to assess

IL-2-induced changes in their relative frequency in blood.

Cluster annotation

Functional annotation of the resulting clusters was performed manually based on the cluster-specific differential expression of the mRNA and protein markers (summarised in **Supplementary Data 1**). Sample tagging information, corresponding to sorting gate information, was used to sub-cluster the five main immune populations (CD4$^+$ CD127^{low}CD25^{hi} Treg; CD4$^+$ CD25$^{-/low}$ Tconv; CD8$^+$ T; CD56^{br} NK and CD56^{dim} NK cells). The use of a bespoke targeted single-cell approach combined with a cell-subset enrichment strategy provided a high-resolution map of the heterogeneity of these cell populations – and particularly of the rare circulating CD4$^+$ Treg and CD56^{br} NK cell subsets.

We note that a consequence of the cell-subset enrichment strategy used in this study is that the frequency of the T and NK cell subsets described in this dataset do not directly represent their frequency in whole blood. The aim of this study was not to identify changes in the global composition of PBMCs, but to specifically focus on the T and NK cell subsets. The pre-purification of the Treg and CD56^{br} NK subsets was central to the resolution of this approach and provided greater power to dissect their functional heterogeneity and investigate how their relative composition was modified by LD-IL-2 immunotherapy

Functional annotation of CD4$^+$ CD127^{low}CD25^{hi} T cell clusters

Owing to our cell-subset enrichment strategy, we obtained a high-resolution map depicting the heterogeneity of CD127^{low}CD25^{hi} T cells in blood, with 13 distinct clusters identified in unstimulated cells (**Supplementary Fig. 4a**) and 12 in *in vitro* stimulated cells (**Supplementary Fig. 4b**). Overall, we found consistency in the functional annotation of the identified subsets in stimulated and unstimulated cells, with a clear demarcation of the naïve and memory subsets.

Expression of the canonical Treg transcription factors *FOXP3* and *IKZF2* (encoding HELIOS) was used to identify three distinct groups of clusters, corresponding to different populations of CD127^{low}CD25^{hi} T cells: (i) CD45RA$^+$ FOXP3$^+$HELIOS$^+$ clusters (depicted in green)

corresponding to thymic-derived naïve Tregs; (ii) CD45RA⁻ FOXP3⁺HELIOS⁺ clusters (depicted

in blue) corresponding to memory Tregs with suppressive function; and (iii) CD45RA⁻ CD25⁺

FOXP3⁻HELIOS⁻ clusters (depicted in red) corresponding to a small subset of Teffs expressing

CD25 likely due to recent activation (**Supplementary Fig. 5**). Additional clusters showing

variable expression of FOXP3 but lack of HELIOS expression (FOXP3⁺HELIOS⁻ clusters) were

depicted in black, and represent a more heterogeneous group of Treg subsets, containing a mix of

thymic-derived and induced Treg subsets.

As expected, most of the cells within the $CD127^{low}CD25^{hi}$ Treg gate showed concomitant

expression of FOXP3 and HELIOS, which is consistent with their largely demethylated *FOXP3*

Treg-specific demethylated region (TSDR)[37], the hallmark of *bona fide* thymic Tregs.

Furthermore, we were able to identify a trajectory of thymic Treg differentiation, originating from

the naïve FOXP3⁺HELIOS⁺ Tregs (cluster 0). Memory FOXP3⁺HELIOS⁺ Tregs displayed more

heterogeneity and included four distinct subsets in unstimulated cells, including a cluster of CD80⁺

Tregs characterised by elevated expression of tissue-homing receptors (cluster 7) and a cluster of

effector Tregs (cluster 1) typically marked by the expression of HLA class II and other effector

Treg markers such as CD39 and GITR (**Supplementary Fig. 4a**). We have also identified a subset

of CD45RA⁺ naïve cells (cluster 2) showing much lower expression of FOXP3 and HELIOS

compared to the classical naïve Treg cluster. This likely corresponds to a subset of

homeostatically-expanded CD45RA⁺ T cells upregulating CD25 that we have previously

characterised[77]. Consistent with this non-Treg profile, these CD25⁺ naïve T cells upregulated the

expression of IL-2 upon *in vitro* stimulation (**Supplementary Fig. 5f**). The expression of IL-2 in

stimulated cells was also a hallmark of the CD25⁺ FOXP3⁻HELIOS⁻ Teff clusters and allowed us

to further refine their functional heterogeneity. Moreover, the relative frequency of CD45RA⁻

FOXP3⁻HELIOS⁻ cells identified in this single-cell dataset is consistent with the frequency of cells

identified by FACS as cytokine-producing FOXP3⁻HELIOS⁻ cells in the $CD127^{low}CD25^{hi}$ Treg

gate that we have previously shown to contain a methylated TSDR[37], further indicating that they

correspond to a small proportion of activated CD25⁺ FOXP3⁻HELIOS⁻ Teffs captured in the

$CD127^{low}CD25^{hi}$ Treg gate.

Functional annotation of CD56$^+$ NK cell clusters

In contrast to T cells, we found much lower heterogeneity in NK cells (**Fig. 4d** and **Supplementary**

Fig. 13). In addition, the technical issue affecting the efficiency of the AbSeq staining on CD56^{br}

NK cells, precluded the use of protein data for the clustering and annotation of the CD56$^+$ NK

cells, which also contributed to a lower resolution of the clusters. Nevertheless, our cell-

enrichment strategy allowed us to generate a comprehensive single-cell map of NK cell

heterogeneity, most notably of the rare, IL-2-sensitive CD56^{br} NK population. We observed

differentiation of CD56^{br} NK cells from a rare progenitor subset marked by the expression of genes

associated with haematopoiesis such as SOX4 and KIT, and characterization of two functional

subsets associated with a trajectory of CD56^{br} NK cell maturation, which was marked by HLA

class II gene expression in the more differentiated cells. In contrast, CD56^{dim} NK cells showed a

distinct transcriptional profile of two distinct subsets, reflecting a gradient of NK cell activation

associated with the acquisition of a cytotoxic profile (**Fig. 4d** and **Supplementary Fig. 13**). These

findings support a distinct functional differentiation between the CD56^{dim} and CD56^{br} subsets,

which allowed clear identification a fraction of CD56^{dim} NK cells sorted in the CD56^{br} gate, as

well as a fraction of CD56^{br} NK cells sorted within the CD56^{dim} gate (**Fig. 4e**).

Differential abundance analysis

To identify specific cell frequency changes across different sampling time points, we calculated

the frequency of each cell type annotated. A cell type was defined as a group of cells from the

same cluster or several similar clusters, after removing cells not sorted from the corresponding

gate. The frequency of each cell type for each participant and each time point was calculated as

the proportion of that cell type within all cells from the same participant, time point and sorting

gate of origin. For each cell type, a two-sided Wilcoxon signed-rank test was performed to compare

the frequencies at Day 0 with the frequencies at Day 27 or Day 55 in the 13 participants selected

for single-cell analysis. Benjamini-Hochberg FDR correction was applied after pooling all

resulting P values. For each cell type and each participant, the log$_2$ fold change values between

corresponding frequency values were calculated and visualised. We note that cells were compared

only if they were from the same sorting gate, as cells from different sorting gates were pooled in
designated proportions that are not biologically relevant.

Generation and normalisation of pseudo-bulk expression data

For the DILfreq dataset, unstimulated and stimulated cells were separately partitioned into five
groups (Treg, Tconv, CD8, CD56^{br} and CD56^{dim}), after removing cells not sorted from the
corresponding gate. In each group, cells from the same participant, time point and stimulation
status were aggregated into one pseudo-bulk sample by summarising raw counts of each mRNA
or AbSeq feature. For the COMBAT and INCOV datasets, the pseudo-bulk expression data for
each participant and each cell type were obtained from the authors, and samples with less than
2,000 total RNA counts were removed. For the INCOV dataset, samples from non-COVID-19,
immunocompromised or immunosuppressed participants were additionally removed.

Differential expression analysis

Differential expression analysis was performed separately for RNA and AbSeq data from raw
pseudo-bulk counts using DESeq2[78]. Specifically, the likelihood ratio test was used, with a full
model including time points and the participants as independent variables, and a reduced model
including only participants as the independent variable. The apeglm method[79] was applied to
shrink the resulting fold change values, and the Benjamini-Hochberg FDR correction was applied
after pooling all resulting P values (**Supplementary Data 2**). Genes with either (i) absolute log2
fold change values equal to or greater than 0.4 and FDR-adjusted P values less than 0.01, or (ii)
FDR-adjusted P values less than 1×10^{-10}, were selected as significantly differentially expressed
genes, unless otherwise noted. Participant-specific $\log_2$ fold change values were calculated directly
from the normalised pseudo-bulk expression data.

Day 55 signature scores

Forty-one genes that were significantly upregulated or downregulated in at least one unstimulated

cell population comparing Day 55 with Day 0 were defined as Day 55 signature genes, from which

the Day 55 signature scores were calculated. Within each dataset, the Day 55 signature score was

defined for each pseudo-bulk sample as the sum of z-scores of normalised expression levels of

upregulated signature genes, subtracted by that of downregulated signature genes. For each

participant and cell type in the DILfrequency dataset, the Δ signature scores were defined as the

signature score differences between Day 27 or Day 55 and Day 0, as indicated.

Pseudo-time trajectory analysis

Pseudo-time trajectory analysis was performed using Slingshot[80] and tradeSeq[81]. First, 10-

dimensional UMAP embeddings were generated for stimulated $CD4^+$ T cells based on RNA and

AbSeq data, as described above. Second, the Slingshot algorithm was applied to UMAP data and

the manually annotated cluster labels, with naïve cells selected as the starting point, and other

parameters set to default. Finally, the resulting pseudo-time data were used as the input for the

tradeSeq algorithm to model the expression levels of each gene along each trajectory.

Data availability

870   The single-cell sequencing data generated in this study have been deposited in Gene Expression

871   Omnibus (GEO) under accession code GSE201197

872   (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE201197).

Code availability

875   The custom code used in the study for data analyses and visualisation has been deposited in

876   Zenodo (https://doi.org/10.5281/zenodo.7116340).

Acknowledgements

We thank all participants in DILT1D and DILfrequency for their generous contribution to this study. The authors also acknowledge the support of the NIHR Cambridge Biomedical Research Centre and the Cambridge Clinical Trial Unit for trial coordination; the NIHR/Wellcome Trust Clinical Research Facility and Addenbrooke's Centre for Clinical Investigation for clinical facilities; the Department of Clinical Immunology, Addenbrooke's Hospital; the JDRF/Wellcome Diabetes and Inflammation laboratory sample processing team (led by Helen Stevens) and information technology and administration team (led by Judy Brown) and data teams at the Cambridge Institute for Medical Research. We thank Shannah Donhou, Sarune Kacinskaite and Heather McMurray, University of Oxford for sample collection and preparation, and members of the Diabetes and Inflammation Laboratory for critical discussion. We thank Justin Whalley, Georgina Kerr, Brian Marsden and Julian Knight, University of Oxford, for providing access to clinical data collected from the COMBAT cohort. We also thank Yapeng Su, and Dan Yuan from Institute for Systems Biology, and Jason D. Goldman from Swedish Medical Center, for providing access to the annotated single-cell data collected from the INCOV cohort.

Funding

This work was supported by the Sir Jules Thorn Trust (13/JTA (OCT2013/DR/1044)), the JDRF (1-SRA-2019-657-A-N), and the NIHR Cambridge Biomedical Research Centre. The Diabetes and Inflammation Laboratory was supported by a strategic award from the Wellcome (107212/A/15/Z) and the JDRF (4-SRA-2017-473-A-A). JYZ was supported by the China Scholarship Council-University of Oxford Scholarship. The research was supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z with additional support from the NIHR Oxford BRC. The University of Cambridge has received salary support for M.L.E. through the National Health Service in the East of England through the Clinical Academic Reserve. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Author contributions

L.S.W., J.A.T. and R.C.F. conceptualised this work and designed the experiments. M.L., L.G. and R.C.F. performed the scRNA-seq experiments. J-Y.Z. led the analysis of the scRNA-seq data with help from F.H. and D.T. M.M. and J.H.M.Y. performed the in vitro suppression experiments and analysed the data under the supervision of T.I.M.T. M.L.P. and R.C.F. performed FACS experiments and analysed the data. J.K., F.W-L. and M.L.E. supervised the DILfrequency study. T.I.M.T. provided conceptual advice on the experiments. J-Y.Z., L.S.W, J.A.T. and R.C.F. wrote the manuscript with input from all authors.

Competing interests

F.W-L. is employed by Vertex Pharmaceuticals; J.A.T. is a member of the GSK Human Genetics Advisory Board. The remaining authors declare no competing interests.

References

1. Koreth, J. *et al.* Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease. *New*
Engl J Med **365**, 2055–2066 (2011).
2. Saadoun, D. *et al.* Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-
Induced Vasculitis. *New Engl J Med* **365**, 2067–2077 (2011).
3. Castela, E. *et al.* Effects of Low-Dose Recombinant Interleukin 2 to Promote T-
Regulatory Cells in Alopecia Areata. *JAMA Dermatol* **150**, 748–751 (2014).
4. von Spee-Mayer, C. *et al.* Low-dose interleukin-2 selectively corrects regulatory T cell
defects in patients with systemic lupus erythematosus. *Ann Rheum Dis* **75**, 1407–1415
(2016).
5. Zhao, T. X. *et al.* Low-dose interleukin-2 in patients with stable ischaemic heart disease
and acute coronary syndromes (LILACS): protocol and study rationale for a randomised,
double-blind, placebo-controlled, phase I/II clinical trial. *BMJ Open* **8**, e022452 (2018).
6. He, J. *et al.* Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus
erythematosus: a randomised, double-blind, placebo-controlled trial. *Ann Rheum Dis* **79**,
141–149 (2020).
7. Klatzmann, D. & Abbas, A. K. The promise of low-dose interleukin-2 therapy for
autoimmune and inflammatory diseases. *Nat Rev Immunol* **15**, 283–294 (2015).
8. Graßhoff, H. *et al. Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases.*
Front Immunol **12**, e648408 (2021).
9. Kolios, A. G. A., Tsokos, G. C. & Klatzmann, D. Interleukin-2 and regulatory T cells in
rheumatic diseases. *Nat Rev Rheumatol* **17**, 749–766 (2021).
10. Ghosh, S. *et al.* Polygenic control of autoimmune diabetes in nonobese diabetic mice. *Nat*
Genet **4**, 404–409 (1993).
11. Todd, J. A. Etiology of Type 1 Diabetes. *Immunity* **32**, 457–467 (2010).
12. Hulme, M. A., Wasserfall, C. H., Atkinson, M. A. & Brusko, T. M. Central Role for
Interleukin-2 in Type 1 Diabetes. *Diabetes* **61**, 14–22 (2011).
13. Yamanouchi, J. *et al.* Interleukin-2 gene variation impairs regulatory T cell function and
causes autoimmunity. *Nat Genet* **39**, 329–337 (2007).
14. Tang, Q. *et al.* Central Role of Defective Interleukin-2 Production in the Triggering of
Islet Autoimmune Destruction. *Immunity* **28**, 687–697 (2008).
15. Hartemann, A. *et al.* Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2
randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol* **1**, 295–
305 (2013).
16. Rosenzwajg, M. *et al.* Low-dose interleukin-2 fosters a dose-dependent regulatory T cell
tuned milieu in T1D patients. *J Autoimmun* **58**, 48–58 (2015).
17. Rosenzwajg, M. *et al.* Low-dose IL-2 in children with recently diagnosed type 1 diabetes:
a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
Diabetologia **63**, 1808–1821 (2020).
18. Todd, J. A. J. *et al.* Regulatory T cell responses in participants with type 1 diabetes after a
single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial.
PLoS Med **13**, e1002139 (2016).

19.   Seelig, E. *et al.* The DILfrequency study is an adaptive trial to identify optimal IL-2
dosing in patients with type 1 diabetes. *JCI Insight* **3**, (2018).

20.   Trzupek, D. *et al.* Single-cell multi-omics analysis reveals IFN-driven alterations in T
lymphocytes and natural killer cells in systemic lupus erythematosus. *Wellcome Open Res*
6, (2021).

21.   Kenefeck, R. *et al.* Follicular helper T cell signature in type 1 diabetes. *J Clin Invest* **125**,
292–303 (2015).

22.   Ferreira, R. C. *et al.* IL-21 production by CD4+ effector T cells and frequency of
circulating follicular helper T cells are increased in type 1 diabetes patients. *Diabetologia*
58, 781–790 (2015).

23.   Ekman, I. *et al.* Circulating CXCR5−PD-1hi peripheral T helper cells are associated with
progression to type 1 diabetes. *Diabetologia* **62**, 1681–1688 (2019).

24.   von Herrath, M. *et al.* Anti-interleukin-21 antibody and liraglutide for the preservation of
β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind,
placebo-controlled, phase 2 trial. *Lancet Diabetes Endocrinol* **9**, 212–224 (2021).

25.   Bell, C. J. M. *et al.* Sustained in vivo signaling by long-lived IL-2 induces prolonged
increases of regulatory T cells. *J Autoimmun* **56**, 66–80 (2015).

26.   Yu, A. *et al.* Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple
Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes.
Diabetes **64**, 2172–2183 (2015).

27.   Trzupek, D. *et al.* Discovery of CD80 and CD86 as recent activation markers on
regulatory T cells by protein-RNA single-cell analysis. *Genome Med* **12**, 55 (2020).

28.   Ito, S. *et al.* Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of
Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. *Mol Ther* **22**, 1388–
1395 (2014).

29.   Humrich, J. Y. *et al.* Low-dose interleukin-2 therapy in refractory systemic lupus
erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. *Lancet*
Rheumatol **1**, e44–e54 (2019).

30.   Uxa, S. *et al.* Ki-67 gene expression. *Cell Death Differ* **28**, 3357–3370 (2021).

31.   di Rosa, F., Cossarizza, A. & Hayday, A. C. To Ki or Not to Ki: Re-Evaluating the Use
and Potentials of Ki-67 for T Cell Analysis. *Front Immunol* **12**, (2021).

32.   Muñoz-Ruiz, M. *et al.* Tracking immunodynamics by identification of S-G2/M-phase T
cells in human peripheral blood. *J Autoimmun* **112**, 102466 (2020).

33.   Ariel, A. *et al.* IL-2 Induces T Cell Adherence to Extracellular Matrix: Inhibition of
Adherence and Migration by IL-2 Peptides Generated by Leukocyte Elastase. *J Immunol*
161, 2465 (1998).

34.   Franitza, S. *et al.* TNF-α Associated with Extracellular Matrix Fibronectin Provides a Stop
Signal for Chemotactically Migrating T Cells. *The Journal of Immunology* **165**, 2738–
2747 (2000).

35.   Wrenshall, L. E., Platt, J. L., Stevens, E. T., Wight, T. N. & Miller, J. D. Propagation and
Control of T Cell Responses by Heparan Sulfate-Bound IL-2. *J Immunol* **170**, 5470
(2003).

36.   Miller, J. D., Clabaugh, S. E., Smith, D. R., Stevens, R. B. & Wrenshall, L. E. Interleukin-
2 is present in human blood vessels and released in biologically active form by
heparanase. *Immunol Cell Biol* **90**, 159–167 (2012).

37.   Ferreira, R. C. *et al.* Cells with Treg-specific FOXP3 demethylation but low CD25 are
1003   prevalent in autoimmunity. *J Autoimmun* **84**, 75–86 (2017).

1004   38.   Singh, S. S. *et al.* Amphiregulin in cellular physiology, health, and disease: Potential use
1005   as a biomarker and therapeutic target. *J Cell Physiol* **237**, 1143–1156 (2022).

1006   39.   West, N. R. *et al.* Oncostatin M drives intestinal inflammation and predicts response to
1007   tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease.
1008   *Nat Med* **23**, 579–589 (2017).

1009   40.   Richard, A. C. *et al.* Targeted genomic analysis reveals widespread autoimmune disease
1010   association with regulatory variants in the TNF superfamily cytokine signalling network.
1011   *Genome Med* **8**, 76 (2016).

1012   41.   Maña, P. *et al.* LIGHT (TNFSF14/CD258) Is a Decisive Factor for Recovery from
1013   Experimental Autoimmune Encephalomyelitis. *J Immunol* **191**, 154–163 (2013).

1014   42.   Ahern, D. J. *et al.* A blood atlas of COVID-19 defines hallmarks of disease severity and
1015   specificity. *Cell* **185**, 916-938 (2022).

1016   43.   Su, Y. *et al.* Multiple early factors anticipate post-acute COVID-19 sequelae. *Cell* **185**,
1017   881-895.e20 (2022).

1018   44.   Whangbo, J. S. *et al.* Functional analysis of clinical response to low-dose IL-2 in patients
1019   with refractory chronic graft-versus-host disease. *Blood Adv* **3**, 984–994 (2019).

1020   45.   Whangbo, J. S. *et al.* Dose-escalated interleukin-2 therapy for refractory chronic graft-
1021   versus-host disease in adults and children. *Blood Adv* **3**, 2550–2561 (2019).

1022   46.   Bielekova, B. *et al.* Regulatory CD56bright natural killer cells mediate
1023   immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis.
1024   *Proc Natl Acad Sci USA* **103**, 5941–5946 (2006).

1025   47.   Melsen, J. E., Lugthart, G., Lankester, A. C. & Schilham, M. W. Human Circulating and
1026   Tissue-Resident CD56bright Natural Killer Cell Populations. *Front Immunol* **7**, 262
1027   (2016).

1028   48.   Ballesteros-Tato, A. *et al.* Interleukin-2 Inhibits Germinal Center Formation by Limiting T
1029   Follicular Helper Cell Differentiation. *Immunity* **36**, 847–856 (2012).

1030   49.   Locci, M. *et al.* Activin A programs the differentiation of human TFH cells. *Nat Immunol*
1031   **17**, 976–984 (2016).

1032   50.   He, J. *et al.* Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets
1033   in patients with systemic lupus erythematosus. *Nat Med* **22**, 991–993 (2016).

1034   51.   Liu, S. M. *et al.* Differential IL-21 signaling in APCs leads to disparate Th17
1035   differentiation in diabetes-susceptible NOD and diabetes-resistant NOD.Idd3 mice. *J Clin*
1036   *Invest* **121**, 4303–4310 (2011).

1037   52.   Crotty, S. T Follicular Helper Cell Biology: A Decade of Discovery and Diseases.
1038   *Immunity* **50**, 1132–1148 (2019).

1039   53.   Ren, H. M., Lukacher, A. E., Rahman, Z. S. M. & Olsen, N. J. New developments
1040   implicating IL-21 in autoimmune disease. *J Autoimmun* **122**, 102689 (2021).

1041   54.   Sage, P. T. & Sharpe, A. H. T follicular regulatory cells. *Immunol Rev* **271**, 246–259
1042   (2016).

1043   55.   Jacobsen, J. *et al.* Expression of Foxp3 by T follicular helper cells in end-stage germinal
1044   centers. *Science* **373**, eabe5146 (2021).

1045   56.   Provine, N. M. & Klenerman, P. MAIT Cells in Health and Disease. *Annu Rev Immunol*
1046   **38**, 203–228 (2020).

57. Tao, H. *et al.* Differential controls of MAIT cell effector polarization by
mTORC1/mTORC2 via integrating cytokine and costimulatory signals. *Nat Commun* **12**,
2029 (2021).
58. Zhou, P. *et al.* Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in
systemic lupus erythematosus. *PLoS Pathog* **17**, e1009858 (2021).
59. Matsumoto, A. *et al.* CIS, a Cytokine Inducible SH2 Protein, is a Target of the JAK-
STAT5 Pathway and Modulates STAT5 Activation. *Blood* **89**, 3148–3154 (1997).
60. Gill, K. L., Gardner, I., Li, L. & Jamei, M. A Bottom-Up Whole-Body Physiologically
Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate
of Subcutaneous Absorption of Therapeutic Proteins. *AAPS J* **18**, 156–170 (2016).
61. Bohnacker, S. *et al.* Mild COVID-19 imprints a long-term inflammatory eicosanoid- and
chemokine memory in monocyte-derived macrophages. *Mucosal Immunol* (2022)
doi:10.1038/s41385-021-00482-8.
62. Phetsouphanh, C. *et al.* Immunological dysfunction persists for 8 months following initial
mild-to-moderate SARS-CoV-2 infection. *Nat Immunol* **23**, 210–216 (2022).
63. Marcovecchio, M. L. *et al.* Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a
phase 2, multicentre, double-blind, randomized, placebo-controlled trial. *Wellcome Open*
Res **5**, (2020).
64. Ferreira, R. C. *et al.* Chronic Immune Activation in Systemic Lupus Erythematosus and
the Autoimmune PTPN22 Trp620 Risk Allele Drive the Expansion of FOXP3+
Regulatory T Cells and PD-1 Expression. *Front Immunol* **10**, 2606 (2019).
65. Sims, E. K. *et al.* Teplizumab improves and stabilizes beta cell function in antibody-
positive high-risk individuals. *Sci Transl Med* **13**, eabc8980 (2021).
66. Quattrin, T. *et al.* Golimumab and Beta-Cell Function in Youth with New-Onset Type 1
Diabetes. *New Engl J Med* **383**, 2007–2017 (2020).
67. Dayan, C. M. *et al.* Preventing type 1 diabetes in childhood. *Science* **373**, 506–510 (2021).
68. Waldron-Lynch, F. *et al.* Rationale and study design of the Adaptive study of IL-2 dose on
regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive
dose finding trial. *BMJ Open* **4**, (2014).
69. Truman, L. A. *et al.* Protocol of the adaptive study of IL-2 dose frequency on regulatory T
cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose,
open-label, response-adaptive study. *BMJ Open* **5**, (2015).
70. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat Methods*
9, 357–359 (2012).
71. Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: Computational Identification of Cell
Doublets in Single-Cell Transcriptomic Data. *Cell Syst* **8**, 281-291.e9 (2019).
72. Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573-3587.e29
(2021).
73. Aitchison, J. *The Statistical Analysis of Compositional Data*. (Chapman & Hall, Ltd.,
1986).
74. McInnes, L., Healy, J. & Melville, J. UMAP: Uniform Manifold Approximation and
Projection for Dimension Reduction. *ArXiv* **arXiv:1802**, (2018).
75. Blondel, V. D., Guillaume, J.-L., Lambiotte, R. & Lefebvre, E. Fast unfolding of
communities in large networks. *Journal of statistical mechanics: theory and experiment*
2008, P10008 (2008).

76.   Itay, T. *et al.* Dissecting the multicellular ecosystem of metastatic melanoma by single-
1093   cell RNA-seq. *Science* **352**, 189–196 (2016).
1094   77.   Pekalski, M. L. *et al.* Postthymic expansion in human CD4 naive T cells defined by
1095   expression of functional high-affinity IL-2 receptors. *J Immunol* **190**, 2554–2566 (2013).
1096   78.   Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion
1097   for RNA-seq data with DESeq2. *Genome Biol* **15**, 1–21 (2014).
1098   79.   Zhu, A., Ibrahim, J. G. & Love, M. I. Heavy-tailed prior distributions for sequence count
1099   data: removing the noise and preserving large differences. *Bioinformatics* **35**, 2084–2092
1100   (2019).
1101   80.   Street, K. *et al.* Slingshot: cell lineage and pseudotime inference for single-cell
1102   transcriptomics. *BMC Genomics* **19**, 477 (2018).
1103   81.   van den Berge, K. *et al.* Trajectory-based differential expression analysis for single-cell
1104   sequencing data. *Nat Commun* **11**, 1201 (2020).
1105

Figures

Figure 1. Interval low-dose IL-2 administered every three days sustained an increased frequency of CD4+ regulatory T cells and CD56br NK cells in blood.

a, Schematic representation of the interval low-dose IL-2 (iLD-IL-2) dosing regimen used in this study. **b**, Gating strategy for the delineation of the five T and NK cell populations assessed by flow cytometry. Values shown represent the average frequency of the respective immune cell population at baseline (Day 0; ± standard error of mean, SEM) of the 18 DILfrequency participants. **c**, Variation (depicted as the %

change from baseline pre-treatment levels) in the frequency of the five assessed immune subsets in blood

(denominator is total T cells for T cell subsets, CD 4$^+$ T cells for the CD 4$^+$ Treg subset and total CD56$^+$

NK cells for NK subsets). Data shown depict the average (± SEM) variation at each visit in the 18

DILfrequency participants treated with the 3-day interval dosing schedule. **d-e**, Absolute numbers of the

assessed CD4$^+$ CD127^{low}CD25^{hi} (Tregs) and CD56^{br} NK cell (**d**), as well as the broader CD4$^+$and CD8$^+$

T and CD56$^+$ NK cell (**e**) subsets in blood. Data shown depict the average (± SEM) numbers at each visit

in the 18 selected participants - treated with either 0.2 ($N = 4$), 0.32 ($N = 12$) or 0.47 ($N = 2$) × 10^6 IU/m^2

IL-2. Dotted lines indicate the average baseline pre-treatment numbers of each immune subset. Plots

depicting the changes of the immune populations shown in **c-e** in each of the individual study participants

are shown in ref. [19]. **f**, Overview of the experimental design employed in this study. Simultaneous

quantification of mRNA ($N = 565$ probes) and surface-expressed proteins ($N = 65$ AbSeq antibodies)

was performed at the single-cell level using the BD Rhapsody system and employing a cell-enrichment

strategy. Equal proportions of flow-sorted cells subsets (30% CD4$^+$ Tregs; 25% CD4$^+$ Tconv and CD8$^+$

T; 12% CD56^{br} NK and 8% CD56^{dim} NK cells) from 13 selected DILfrequency participants treated with

the 3-day dosing interval were profiled at three distinct time points: (i) prior to IL-2 treatment (Day 0),

(ii) three days after the penultimate dose of IL-2 (Day 27), and (iii) one month after the last dose of IL-

2 (Day 55). **g**, Uniform Manifold Approximation and Projection (UMAP) plot depicting the 15 clusters

identified from the clustering of the 482,531 unstimulated cells profiled in this study. Clusters were

manually annotated based on the expression of key differentially expressed mRNA and protein markers.

Light grey cells correspond to CD56^{br} NK cells without sorting gate information.

1135

1137

Figure 2. Interval low-dose IL-2 immunotherapy selectively expands FOXP3+HELIOS+ Tregs.

a, UMAP plot depicting the 13 clusters identified from the clustering of the 149,202 unstimulated cells sorted from the CD127^{low}CD25^{hi} Treg gate profiled in this study. Clusters were manually annotated based on the expression of key differentially expressed mRNA and protein markers. Clusters corresponding to: (i) naïve Tregs (defined as CD45RA$^+$ FOXP3$^+$HELIOS$^+$); (ii) memory Tregs (defined as CD45RA$^-$ FOXP3$^+$HELIOS$^+$); or (iii) CD25$^+$ FOXP3$^-$HELIOS$^-$ Teffs (defined as CD45RA$^-$ FOXP3$^-$ HELIOS$^-$) are annotated in green, blue and red, respectively. All other miscellaneous clusters not conforming to this definition are annotated in black. **b**, Relative frequency changes of naïve FOXP3$^+$HELIOS$^+$ Tregs, memory FOXP3$^+$HELIOS$^+$ Tregs, and CD25$^+$ FOXP3$^-$HELIOS$^-$ Teffs clusters on Day 27 compared to the baseline pre-treatment (Day 0) levels, for unstimulated cells. Relative frequency of a certain cluster was calculated as the number of cells in that cluster divided by the total

number of cells sorted from the Treg gate. **c,d** Corresponding UMAP plot (**c**) and relative frequency for

the identified subsets (**d**) for the 115,153 *in vitro* stimulated CD4$^+$ T cells sorted from the

CD127^{low}CD25^{hi} Treg gate. **e**, Absolute cell numbers of naïve FOXP3$^+$HELIOS$^+$ Tregs, memory

FOXP3$^+$HELIOS$^+$ Tregs, and CD25$^+$ FOXP3$^-$HELIOS$^-$ Teffs on Day 0, Day 27 and Day 35, for

unstimulated (circles connected by solid lines) and stimulated (triangles connected by dashed lines) cells.

Absolute cell numbers were calculated as the total absolute number of Tregs measured by FACS

multiplied by the relative frequency of a certain cluster. **f**, Per-cell Treg suppression efficiency for each

time point. Treg suppression efficiency was assessed *in vitro* by culturing CD4$^+$CD25^{hi}CD127^{low} Tregs

with autologous CD4$^+$CD25$^{-/low}$CD127$^+$ Teffs at various ratios (x axis) and represented as the decrease

in Teff proliferation compared with the control condition (y axis). PBMCs from 12 participants sampled

on Day 0, Day 24 and Day 55 were used for this assay. *FDR-adjusted *P* < 0.05; two-sided Wilcoxon

signed-rank test comparing the relative frequency of the subsets between Day 27 and Day 0. In **b**, **d** and

f, each dot represents cells from a single participant. Dots with the same colour represent the same

participant.

1163

Figure 3. Low-dose IL-2 treatment inhibits the differentiation of IL-21-producing CD4+ T cells

a, Expression levels of 30 differentially expressed markers in the four assessed IL-21-producing CD4+ T cell subsets from *in vitro* stimulated CD4+ T cells: CXCR5+ T$_{CM}$ and CXCR5^{low}IL-21+ sorted from the CD25$^{-/low}$ Tconv gate; and CD25+ T$_{FH}$ and CD25+IL-21+ T$_{FH}$ sorted from the CD127^{low}CD25^{hi} Treg gate. Expression levels are based on normalised and scaled single-cell expression data. Gene markers

were selected based on pairwise differential expression analysis among the four assessed clusters. **b**,

Expression of CXCR5 (AbSeq) and *IL21* in the four assessed IL-21$^+$ CD4$^+$ T cell subsets from *in vitro*

stimulated cells. **c**, UMAP plot depicting the clustering of *in vitro* stimulated CD4$^+$ T cells (N = 209,543

cells). Cells are coloured according to the respective IL-21$^+$ cluster assignment. Dark grey and light grey

denote cells sorted from the CD127^{low}CD25^{hi} Treg gate and CD25$^{-/low}$ Tconv gate, respectively, that are

not in IL-21$^+$ clusters (**c**); or by normalised and scaled IL-21 expression levels (**d**). **e**, Gene expression

changes between IL-21$^+$ and IL-21$^-$ cells within each of the four assessed IL-21$^+$ CD4$^+$ T cell clusters.

Fold change values were calculated from pseudo-bulk expression data. Genes with absolute log$_2$ fold

change values equal to or greater than 1.2 and FDR-adjusted *P* values less than 0.01 in at least one cluster

were selected. **f**, Relative frequency changes of IL-21$^+$ cells within the two CD4$^+$ T cell subsets

displaying higher expression levels of IL-21: the CXCR5^{low}IL-21$^+$ subset (left panel) and the CD25$^+$IL-

21$^+$ T$_{FH}$ subset (right panel), comparing Day 27 and Day 55 with Day 0, respectively. Each dot represents

cells from a single participant. Dots with the same colour represent the same participant. *P* values were

calculated by comparing the relative frequency values between the two time points using a two-sided

Wilcoxon signed-rank test.

1186

1188

Figure 4. IL-2 treatment reduces the frequency of innate-like CD8$^+$ MAIT and V$_{\gamma 9}$V$_{\delta 2}$ T cells in circulation and selectively expands the IL-2 sensitive CD56^{br} NK cell subset.

a, UMAP plot depicting the clustering of the 93,379 unstimulated CD8$^+$ T cells profiled in this study. Clusters were manually annotated based on the expression of key differentially expressed mRNA and protein markers. **b**, Relative frequency changes of five selected CD8$^+$ T cell clusters on Day 27 compared

to the baseline pre-treatment (Day 0) levels, for unstimulated cells. **c**, Relative frequency of the innate-

like mucosal-associated invariant T cell (MAIT; left panel) and $V_{\gamma 9}V_{\delta 2}$ T cell (right panel) clusters on

Day 0, Day 27, and Day 55. Each line represents cells from a participant. Lines with the same colour

represent the same participant. **d**, UMAP plot depicting the clustering of the 118,625 unstimulated NK

cells profiled in this study. Clusters were manually annotated based on the expression of key

differentially expressed mRNA and protein markers. **e**, UMAP plot as in **d**, split and coloured by FACS

sorting gates of origin. **f-g**, Relative frequency changes of five selected CD56^{br} (**f**) or CD56^{dim} (**g**) NK

cell clusters on Day 27 compared to the baseline pre-treatment (Day 0) levels, for unstimulated cells.

"CD56^{dim} cells sorted as CD56^{br}" represents the fraction of cells sorted from the CD56^{br} NK cell gate

that are found in clusters that predominantly consists of CD56^{dim} NK cells (ie. Clusters 0 and 3).

Conversely, "CD56^{br} cells sorted as CD56^{dim}" represents the fraction of cells sorted from the CD56^{dim}

NK cell gate that are found in clusters that predominantly consists of CD56^{br} NK cells (ie. Clusters 1, 2

and 4). In **b**, **f**, and **g**, the relative frequency of a certain cluster is calculated as the number of cells in

that cluster divided by the total number of cells sorted from the CD8 (**b**), CD56^{br} (**f**) or CD56^{dim} (**g**) NK

cell gate. Each dot represents cells from a single participant. Dots with the same colour represent the

same participant. Asterisks denote statistically significant differences (FDR-adjusted $P < 0.05$; two-sided

Wilcoxon signed-rank test) in cell population frequencies between Day 27 and Day 0.

1211

1213

Figure 5. IL-2 treatment selectively modulates gene expression of CD25[hi] Tregs and CD56[br] NK cells at Day 27.

a-b, Volcano plots depicting gene expression changes between Day 0 and Day 27 for the five assessed immune populations, for unstimulated (**a**) and stimulated (**b**) cells. Significantly differentially expressed genes are coloured in red (upregulated genes) or blue (downregulated genes). Names of the top five up- and downregulated genes as defined by fold change are labelled on each panel. **c**, Differential expression of Day 27 signature genes. Day 27 signature genes are defined as the 40 genes that are significantly

1221 differentially expressed in at least one cell population comparing Day 27 with Day 0. Dot colours represent

1222 log$_2$ fold change between Day 0 and Day 27. Larger dots represent genes that are significantly differentially

1223 expressed in a certain cell population. Manually annotated signature gene subsets are labelled with dashed

1224 boxes.

1226

Figure 6. Interval low-dose IL-2 immunotherapy induces a long-lasting anti-inflammatory gene expression signature

a, Differential expression of Day 55 signature genes. Day 55 signature genes were defined as the 41 genes significantly differentially expressed in at least one cell population comparing Day 55 with Day

0. Dot colours represent log$_2$ fold-change between Day 0 and Day 55. Larger dots represent significantly

differentially expressed genes. **b**, Participant-specific differential expression in CD8$^+$ T cells comparing

Day 27 (top panel) or Day 55 (bottom panel) with Day 0. Top 5 up- and downregulated genes as defined

by Day 55/Day 0 fold-change in CD8$^+$ T cells. Participant labels are coloured by their respective IL-2

dose ($\times 10^6$ IU/m^2): 0.2 (cyan), 0.32 (gray), 0.47 (purple). **c**, Day 55 signature scores by participant for

each time point and cell type. Each participant is represented by a different colour. *P* values were

calculated using a two-tailed paired t test comparing Day 27 or Day 55 with Day 0, respectively. **d-e**,

Variation in the mean expression scores of Day 55 signature genes across the five major cell types (mean

Δ signature score) between Day 27 and Day 0 (**d**) and between Day 55 and Day 0 (**e**) for each participant.

Participants were stratified by IL-2 dose. *P* values were calculated using linear regression. In d-**e**, average

values of the Day 55 signature in all five cell types are shown for each participant.

1242

1244

Figure 7. The IL-2-induced Day 55 anti-inflammatory gene expression signature is reversed in COVID-19 patients

a, Differential expression of the 41 identified Day 55 signature genes in COVID-19 patients. Dot colours represent log_2 fold-change between healthy controls and community COVID-19 patients from the COMBAT study[42]. Larger dots represent significantly differentially expressed genes in a

certain cell population. **b-c** Day 55 gene signature scores plotted against the time since COVID-19

symptoms in the COMBAT (**b**) and INCOV[43] (**c**) cohorts. The Day 55 gene signature score was

based on expression levels of the 41 identified Day 55 signature genes. Each dot represents a pseudo-

bulk sample from a certain participant and time point. Up to three longitudinal samples may

originate from the same participant. COVID-19 patients were stratified according to their maximum

disease severity. Dashed black lines represent smooth curves fitted by locally weighted scatterplot

smoothing (LOWESS). **d**, Correlation between the differential expression of the Day 55 signature

genes and Component 187 from the COMBAT study. Of the 1,419 genes included in Component

187, a gene expression signature induced by COVID-19, 77 are also present in the target

transcriptional panel used in this study. The effects of IL-2 immunotherapy and COVID-19 infection

on the induction of these genes are compared by correlating Component loading score (y axis) with

log2 fold change (Day 55/Day 0) in the CD8 population after IL-2 treatment (x axis). The positive

and negative values in Component 187 loading scores represent the up- and downregulation of the

corresponding gene, respectively, after COVID-19 infection. Larger dots represent genes with FDR-

adjusted P values < 0.01, comparing Day 55 and Day 0 expression levels. **e**, Enrichment of Day 55

signature genes in each gene expression component reported in the COMBAT study. Each dot

represents a disease-associated gene expression component in the COMBAT study. Dot sizes

represent the number of shared genes between a certain component and the 41 Day 55 signature

genes. Only top 50 components ranked by their odds ratios of enrichment (x axis) are shown.

Colours represent cluster membership as reported in the COMBAT study. Components in the same

cluster are associated with diseases in a similar way. Cluster 3 is associated with all severity groups

of COVID-19. **f**, Component 187 sample loading scores plotted against time since symptoms for

COVID-19 patients. Each dot represents a patient. Patients are stratified by their maximum COVID-

19 severity.

1274

Supplementary Figures

1277

Supplementary Figure 1. Flow cytometric characterisation of the effector memory CD4$^+$ T and CD56$^+$ NK cell populations.

a, Gating strategy for the delineation of CD4$^+$ effector memory T cells (T$_{EM}$). **b-c**, Variation (depicted as the % change from pre-treatment baseline levels) in the frequency of CD4$^+$ T$_{EM}$ (**b**), or the ratio between CD4$^+$ Tregs and T$_{EM}$ cells (**c**) during the course of the study. Baseline levels (mean +/- SEM): CD4$^+$ T$_{EM}$

$= 10.4\%$ +/- 1.39; CD4$^+$ Treg:T$_{EM}$ ratio $= 0.76$ +/- 0.07. **d-f,** Variation (depicted as the % change from

pre-treatment baseline levels) in the relative frequency of CD56^{br} NK cells within the total CD3$^-$CD56$^+$

NK cell gate (**d**), and in the absolute number of CD56^{br} (**e**) and CD56^{dim} (**f**) NK cells in blood during the

course of the study. Baseline levels (mean +/- SEM): CD56^{br} $= 6.2\%$ +/- 0.55; CD56^{br} Number (x10^9/L)

$= 0.011$ +/- 0.001; CD56^{dim} Number (x10^9/L) $= 0.18$ +/- 0.02. Frequencies of the assessed immune subsets

were determined by flow cytometry in the 18 DILfrequency participants treated with the 3-day interval

dosing schedule. Data shown depict the average ($\pm$ SEM) variation of the assessed immune subsets at

each visit and were stratified according to the IL-2 dose.

1292

Supplementary Figure 2. Integration of the single-cell multiomics data.

a-b, Uniform Manifold Approximation and Projection (UMAP) plot depicting the clustering of the 460,941 unstimulated cells profiled in this study. Cells were coloured according to the corresponding oligo-conjugated barcode indicative of the respective FACS sorting gate (**a**), or according to the participant of origin (**b**). Untagged cells in **b** (labelled as 'Tag N/A') correspond to CD56br NK cells, where we observed a suboptimal sample tagging efficiency, resulting in a significant fraction (37.2% in unstimulated cells) of CD56br NK cells with missing sample barcode information. **c**, Relative proportion of cells from each individual participant in each of the flow-sorted unstimulated immune cell populations. Areas of grey circles represent total cell numbers in each immune cell population. **d-e**, UMAP plots depicting the clustering of the 323,839 cells profiled in this study following a short (90 min) *in vitro* stimulation with PMA + ionomycin. Cells were coloured according to the corresponding oligo-conjugated barcode indicative of the respective FACS sorting gate (**d**), or to the donor information (**e**). Untagged cells in panel a (labelled as 'Tag N/A') correspond to CD56br NK cells, where we observed a suboptimal sample

1306 tagging efficiency resulting in a significant fraction (44.3% in the *in vitro* stimulated cells) of CD56br NK

1307 cells with missing sample barcode information. **f**, Relative proportion of cells from each individual

1308 participant in each of the flow-sorted stimulated immune cell populations. Areas of grey circles represent

1309 total cell numbers in each immune cell population.

1310

Supplementary Figure 3. Identification of proliferating cells.

a, UMAP plot depicting the expression of the cell-cycle signature score in each unstimulated single-cell, calculated by summarising the expression levels of 11 pre-selected genes related to cell cycle. **b**, Frequency of proliferating cells in each immune subset identified by the single-cell multiomics analysis. Proliferating cells were defined as the proportion of cells in the identified cycling clusters from each of the 5 sorted immune populations at Days 0, 27 and 55. **c-d**, Frequency of Ki-67[+] cells within each of the 5 assessed immune populations in T1D patients treated with a single (DILT1D; **c**) or with the 3-day interval dosing schedule (DILfrequency; **d**). Ki-67 protein levels were assessed by intracellular flow cytometry in 6 patients from the DILT1D (treated with doses ranging from 0.6-1.5 x 10^6 IU/m^2) and five patients from the DILfrequency (treated with interval doses ranging from 0.2-0.32 x 10^6 IU/m^2). IL-2 dosing days are depicted in red in the x axis.

1325

Supplementary Figure 4. Functional annotation of the CD4$^+$ CD127^{low}CD25^{hi} T cell subsets.

a-b, Expression levels of selected differentially expressed markers delineating the functional subsets in the unstimulated (**a**) and *in vitro* stimulated (**b**) CD4$^+$ T cells sorted from the CD127^{low}CD25^{hi} Treg gate. The size of the dots represents the frequency of the marker in the respective cluster and the colour brightness represents the relative expression level. Protein markers (AbSeq) are shown on the left section of the plots and mRNA markers on the right section. Clusters corresponding to: (i) naïve Tregs (defined as CD45RA$^+$ FOXP3$^+$HELIOS$^+$); (ii) memory Tregs (defined as CD45RA$^-$ FOXP3$^+$HELIOS$^+$); or (iii)

1333   CD25$^+$ FOXP3$^-$HELIOS$^-$Teffs (defined as CD45RA$^-$ FOXP3$^-$HELIOS$^-$) are annotated in green, blue

1334   and red, respectively. All other miscellaneous clusters not conforming to this definition are annotated in

1335   black.

Supplementary Figure 5. Expression of *FOXP3*, *IKZF2* (HELIOS) and *IL2* differentiate functional CD4$^+$ Treg and CD4$^+$ Tconv subsets.

a-b, UMAP plots depicting the expression of the canonical Treg transcription factors *FOXP3* (**a**) and *IKZF2* (encoding HELIOS; **b**) in the unstimulated cells sorted from the CD4$^+$ CD127^{low}CD25^{hi} Treg gate. **c**, Distribution of expression levels of *FOXP3* and *IKZF2* in the identified unstimulated CD127^{low}CD25^{hi} CD4$^+$ T cell clusters. **d-e**, UMAP plots depicting the expression of the canonical Treg transcription factors *FOXP3* (**d**) and *IKZF2* (**e**) in the *in vitro* stimulated cells. **f**, Histograms depicting the expression of *FOXP3*, *IKZF2* and *IL2* in the identified *in vitro* stimulated clusters. Clusters corresponding to: (i) naïve Tregs (defined as CD45RA$^+$ FOXP3$^+$HELIOS$^+$); (ii) memory Tregs (defined as CD45RA$^-$ FOXP3$^+$HELIOS$^+$); or (iii) CD25$^+$ FOXP3$^-$HELIOS$^-$Teffs (defined as CD45RA$^-$ FOXP3$^-$ HELIOS$^-$) are annotated in green, blue and red, respectively. All other miscellaneous clusters not conforming to this definition are annotated in black.

1350

Supplementary Figure 6. Differential abundance analysis reveals a transient increased frequency of FOXP3$^+$HELIOS$^+$ Tregs following ld-IL2 treatment.

a-b, Relative frequency changes of all the identified unstimulated (**a**) or *in vitro* stimulated (**b**) CD127^{low}CD25^{hi} T cell clusters between Day 0 and Day 27 (top panels) or Day 55 (bottom panels). Clusters corresponding to: (i) naïve Tregs (defined as CD45RA$^+$ FOXP3$^+$HELIOS$^+$), (ii) memory Tregs (defined as CD45RA$^-$ FOXP3$^+$HELIOS$^+$), and (iii) CD25$^+$ FOXP3$^-$HELIOS$^-$Teffs (defined as CD45RA$^-$ FOXP3$^-$HELIOS$^-$) are annotated in green, blue and red, respectively. All other miscellaneous clusters not conforming to this definition are annotated in black. Asterisks denote statistically significant differences (two-sided Wilcoxon signed-rank test) in cell population frequencies between the two time points. **c-d**, Relative frequency changes of unstimulated (**c**) or *in vitro* stimulated (**d**) naïve FOXP3$^+$HELIOS$^+$ Treg, memory FOXP3$^+$HELIOS$^+$ Treg, and CD25$^+$ FOXP3$^-$HELIOS$^-$Teff clusters in blood between Day 0 and Day 55. In **a-d**, each dot represents cells from a single participant. Dots with the same colour represent the same participant.

1365

Supplementary Figure 7. Analysis of circulating CD4$^+$ CD25$^{-/low}$ conventional T cells

a, UMAP plot depicting the clustering of the 108,722 unstimulated CD4$^+$ T cells sorted from the CD25$^{-/low}$ Tconv gate profiled in this study. Clusters were manually annotated based on the expression of key differentially expressed mRNA and protein markers. **b**, Expression levels of selected differentially expressed markers delineating the functional subsets in the unstimulated CD4$^+$ T cells sorted from the CD25$^{-/low}$ Tconv gate. The size of the dots represents the frequency of the marker in the respective cluster and the colour brightness represents the relative expression level. Protein markers (AbSeq) are shown on the left section of the plots and mRNA markers on the right section. **c,** Relative frequency changes of all identified unstimulated CD4$^+$ CD25$^{-/low}$ Tconv clusters in blood at Day 27 (top panel) or Day 55 (bottom panel) compared to the baseline pre-treatment (Day 0) levels. **d-f**, Plots corresponding to **a-c**, for the 93,856 *in vitro* stimulated CD4$^+$ T cells sorted from the CD25$^{-/low}$ Tconv gate.

1379

Supplementary Figure 8. Pseudo-time analysis reveals trajectories of Treg and T_{FH} differentiation
in *in vitro* stimulated CD4$^+$ T cells.

a, UMAP plot depicting the Treg differentiation trajectory identified by Slingshot pseudo-time
analysis. **b**, Pseudo-time distribution of cells associated with the Treg trajectory, stratified by cluster
labels. **c**, Fitted expression curves of selected canonical Treg genes by pseudo-time. **d**, Pseudo-time
distribution of cells associated with the Treg trajectory, stratified by time points. **e**, UMAP plot
depicting the T_{FH} differentiation trajectory identified by Slingshot pseudo-time analysis. **f**, Pseudo-
time distribution of cells associated with the T_{FH} trajectory, stratified by cluster labels. **g**, Fitted
expression curves of selected canonical T_{FH} genes by pseudo-time. **h**, Pseudo-time distribution of
cells associated with the T_{FH} trajectory, stratified by time points. Data from **a-h** were generated from
in vitro stimulated CD4$^+$ T cells.
1391

1393

Supplementary Figure 9. Replication of the ratio of naïve:memory Tregs by FACS

a, Gating strategy for the delineation of the naïve (CD45RA$^+$) and memory (CD45RA$^-$) compartment by flow cytometry within cells sorted from the CD4$^+$ CD127^{low}CD25^{hi} Treg gate. **b**, Ratio between naïve and memory cells within the CD4$^+$ CD127^{low}CD25^{hi} Treg gate at the three assessed timepoints (Day 0, Day 27 and Day 55). The connecting line represents the median naïve:memory ratio in the 13 participants selected for single-cell analysis at each time point. **c**, Variation (depicted as the % change from baseline pre-treatment levels) in the naïve:memory ratio within the CD4$^+$ CD127^{low}CD25^{hi} Treg gate assessed by flow cytometry. Data shown depict the average (±SEM) variation at each visit for the 13 participants selected for single-cell analysis. **d**, Correlation between the naïve:memory ratio within CD4$^+$ CD127^{low}CD25^{hi} T cells (left panel), or the corresponding ranks (right panel), obtained from FACS data (x axis) and that estimated from single-cell sequencing data (y axis). **e**, Correlation between the frequency of naïve (CD45RA$^+$; left panel) and memory (CD45RA$^-$; right panel) cells within CD127^{low}CD25^{hi} T cells obtained from FACS data (x axis) and that obtained from single-cell sequencing data (y axis). In **b**, **d** and **e**, each dot represents a sample, with colours and shapes representing participants and time points of origin, respectively. In **d-e**, linear regression lines are shown in black, and 95% confidence intervals of the regression estimate are shown in grey shades.

1411

Supplementary Figure 10. Delineation of Treg subsets by FACS

a, Gating strategy for the delineation of the FOXP3+HELIOS+ Treg, FOXP3+HELIOS− Treg and CD45RA− FOXP3−HELIOS− Teff subsets by flow cytometry. **b-c** Variation (depicted as the % change from baseline pre-treatment levels) in the frequency of FOXP3+HELIOS+ (blue), FOXP3+HELIOS− (black) and CD45RA− FOXP3−HELIOS− (red) cells within the CD127^{low}CD25^{hi} gate in patients treated

with a single dose (DILT1D; **b**) or with the 3-day interval dosing schedule (DILfrequency; **c**). Baseline levels (mean +/- SEM): (i) DILT1D: FOXP3$^+$HELIOS$^+$ = 71.5% +/- 1.47, FOXP3$^+$HELIOS$^-$ = 15.6% +/- 1.63 and CD45RA$^-$ FOXP3$^-$HELIOS$^-$ = 4.7% +/- 0.44; (ii) DILfrequency: FOXP3$^+$HELIOS$^+$ = 66.9% +/- 2.0, FOXP3$^+$HELIOS$^-$ = 19.8% +/- 1.60 and CD45RA$^-$ FOXP3$^-$HELIOS$^-$ = 8.0% +/- 1.02. **d-e**, Variation (depicted as the % change from baseline pre-treatment levels) in the frequency of the FOXP3$^+$HELIOS$^+$ Treg, FOXP3$^+$HELIOS$^-$ Treg and CD45RA$^-$ FOXP3$^-$HELIOS$^-$ Teff subsets in patients treated with a single dose (**d**) or with the 3-day interval dosing schedule. Baseline levels (mean +/- SEM): (i) DILT1D: FOXP3$^+$HELIOS$^+$ = 5.0% +/- 0.54, FOXP3$^+$HELIOS$^-$ = 1.2% +/- 0.24 and CD45RA$^-$ FOXP3$^-$HELIOS$^-$ = 0.34% +/- 0.06; (ii) DILfrequency: FOXP3$^+$HELIOS$^+$ = 4.2% +/- 0.44, FOXP3$^+$HELIOS$^-$ = 1.3% +/- 0.22 and CD45RA$^-$ FOXP3$^-$HELIOS$^-$ = 0.49% +/- 0.05. (**e**). Data were generated by intracellular flow cytometry in 6 patients from the DILT1D (treated with doses ranging from 0.6-1.5 x 10^6 IU/m^2) and 5 patients from the DILfrequency (treated with interval doses ranging from 0.2-0.32 x 10^6 IU/m^2). IL-2 dosing days are depicted in red in the x axis.

1431

Supplementary Figure 11. Interval low-dose IL-2 treatment does not affect the frequency of CD25^{-}/^{low} FOXP3^{+} T cells

a, Identification of FOXP3^{+} within cells sorted from the CD25$^{-/low}$ Tconv gate. FOXP3^{+} cells were defined as cells with one or more counts of *FOXP3* RNA detected. Data was generated from the analysis of the 13 DILfrequency donors selected for the single-cell multiomics analysis. **b**, Box and whiskers plot depicts the frequency of FOXP3^{+} cells within the CD25$^{-/low}$ Tconv gate at Days 0, 27 and 55. Each dot represents a sample, with colours and shapes representing participants and time points of origin, respectively. **c**, Gating strategy for the delineation of CD25$^{-/low}$ FOXP3^{+} T cells by flow cytometry. **d-e** Frequency of CD25$^{-/low}$ FOXP3^{+} T cells in patients treated with a single dose (DILT1D; **d**) or with the 3-day interval dosing schedule (DILfrequency; **e**). **f-g**, Variation (depicted as the % change from baseline pre-treatment levels) in the frequency of the CD25$^{-/low}$ FOXP3^{+}T cells in patients treated with a single dose (**f**) or with the 3-day interval dosing schedule (**g**). Data were generated by intracellular flow cytometry in six patients from the DILT1D (treated with doses ranging from 0.6-1.5 x 10^6 IU/m^2) and patients from the DILfrequency (treated with interval doses ranging from 0.2-0.32 x 10^6 IU/m^2). IL-2 dosing days are depicted in red in the x axis.

1449

Supplementary Figure 12. Functional annotation of CD8$^+$ T cells.

a, Expression of selected differentially-expressed markers delineating the functional subsets identified from the 13 clustering of the 93,621 unstimulated CD8$^+$ T cells profiled in this study. The size of the dots represents the frequency of the marker in the respective cluster and the colour brightness represents the relative expression level. Protein markers (AbSeq) are shown on the left section of the plots and mRNA markers on the right section. **b,** Relative frequency changes of all identified CD8$^+$ T cell clusters on Day 27 (top panel) or Day 55 (bottom panel) compared to the baseline pre-treatment levels. **c**, UMAP plot depicting the clustering of *in vitro* stimulated CD8$^+$ T cells. Clusters were manually annotated based on the expression of key differentially expressed mRNA and protein markers. **d**, Relative frequency changes of the 14 identified stimulated CD8$^+$ T cell clusters at Day 27 compared to the baseline pre-treatment (Day 0) levels.

1461

Supplementary Figure 13. Functional annotation of CD56$^+$ NK cells.

a, Expression of selected differentially-expressed markers delineating the five functional subsets

identified from the clustering of the 99,169 unstimulated CD56$^+$ NK cells profiled in this study. The size

of the dots represents the frequency of the marker in the respective cluster and the colour brightness

represents the relative expression level. Protein markers (AbSeq) are shown on the left section of the

plots and mRNA markers on the right section. The dotted red line separates the clusters corresponding

to either CD56^{br} (top) and CD56^{dim} NK cells (bottom). **b-c**, Relative frequency changes of all identified

unstimulated CD56^{br} (**b**) and CD56^{dim} (**c**) NK cell clusters on Day 55 compared to the baseline pre-

treatment levels. **d**, UMAP plot depicts the clustering of *in vitro* stimulated CD56$^+$ NK cells. **e-f** Relative

frequency changes of all identified clusters of cells sorted from either the CD56^{br} (**e**) or CD56^{dim} (**f**) NK

cell gates following *in vitro* stimulation on Day 27 compared to the baseline pre-treatment (Day 0) levels.

1474

Supplementary Figure 14. Induction of the anti-inflammatory gene expression signature at Day 55 is IL-2 dose-dependent and is detected in all T and NK cell populations

a, Volcano plots depicting gene expression changes between Day 0 and Day 55 for the five assessed immune populations, for unstimulated (left panels) and stimulated (right panels) cells. Significantly differentially expressed genes are coloured in red (upregulated genes) or blue (downregulated genes). The top five up- and downregulated genes (as defined by fold change) are labelled on each panel. **b**, Principal component analysis (PCA) correlating gene expression changes with dose levels. PCA was performed on log₂ fold-change values of Day 55 signature genes on Day 27 in CD8⁺ T cells. Each dot represents a participant, with colours indicating IL-2 dose levels. Vectors representing the gene loading

1485   scores of PC1 and PC2 are shown on the right panel, with genes up- and downregulated on Day 55

1486   shown in red and blue, respectively. **c**, Day 55 signature scores by participant for each time point. Each

1487   participant is represented by a different colour. **d**, Day 55 signature scores plotted against IL-2 dose. The

1488   average value of the Day 55 signature score in the five cell types is shown for each participant.

1489

1491

Supplementary Figure 15. Expression of anti-inflammatory gene expression in COVID-19 patients

a, Day 55 signature scores plotted against the time since COVID-19 symptoms in the COMBAT cohort in NK cells, B cells and mononuclear phagocytes (MNP). **b**, Day 55 signature scores plotted against the time since COVID-19 symptoms in the INCOV cohort in CD4$^+$ T cells, CD8$^+$ T cells, NK cells and

1496   monocytes. In **a** and **b**, each dot represents a pseudo-bulk sample from a certain participant and time

1497   point. Up to three longitudinal samples may originate from the same participant. COVID-19 patients

1498   were stratified according to their maximum disease severity. Dashed black lines represent smooth curves

1499   fitted by locally weighted scatterplot smoothing (LOWESS).

1500

Supplementary Information

Supplementary Table 1. Baseline characteristics of study participants

Supplementary Table 2. Targeted mRNA, protein (AbSeq) and immunostaining panels used in this study

Supplementary Table 3. Characteristics of COMBAT study participants with single-cell data available

Supplementary Data 1. Summary of the cluster-specific RNA and AbSeq markers used for cell type annotation

Supplementary Data 2. Differential expression between Day 0 and Day 27 or Day 55 analysed using DESeq2